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A B S T R A C T
Background
Rapid detection of tuberculosis (TB) among people living with human immunodeficiency virus (HIV) is a global health priority.
HIV-associated TB may have different clinical presentations and is challenging to diagnose. Conventional sputum tests have reduced
sensitivity in HIV-positive individuals, who have higher rates of extrapulmonary TB compared with HIV-negative individuals. The
lateral flowurine lipoarabinomannan assay (LF-LAM) is a new, commercially available point-of-care test that detects lipoarabinomannan
(LAM), a lipopolysaccharide present in mycobacterial cell walls, in people with active TB disease.
Objectives
To assess the accuracy of LF-LAM for the diagnosis of active TB disease in HIV-positive adults who have signs and symptoms suggestive
of TB (TB diagnosis).
To assess the accuracy of LF-LAM as a screening test for active TB disease in HIV-positive adults irrespective of signs and symptoms
suggestive of TB (TB screening).
Search methods
We searched the following databases without language restriction on 5 February 2015: the Cochrane Infectious Diseases Group Spe-
cialized Register; MEDLINE (PubMed,1966); EMBASE (OVID, from 1980); Science Citation Index Expanded (SCI-EXPANDED,
from 1900), Conference Proceedings Citation Index-Science (CPCI-S, from 1900), and BIOSIS Previews (from 1926) (all three using
the Web of Science platform; MEDION; LILACS (BIREME, from 1982); SCOPUS (from 1995); the metaRegister of Controlled
Trials (mRCT); the search portal of the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP);
and ProQuest Dissertations & Theses A&l (from 1861).
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Selection criteria
Eligible study types included randomized controlled trials, cross-sectional studies, and cohort studies that determined LF-LAM accuracy
for TB against a microbiological reference standard (culture or nucleic acid amplification test from any body site). A higher quality
reference standard was one in which two or more specimen types were evaluated for TB, and a lower quality reference standard was
one in which only one specimen type was evaluated for TB. Participants were HIV-positive people aged 15 years and older.
Data collection and analysis
Two review authors independently extracted data from each included study using a standardized form. We appraised the quality of
studies using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. We evaluated the test at two different cut-
offs: (grade 1 or 2, based on the reference card scale of five intensity bands). Most analyses used grade 2, the manufacturer’s currently
recommended cut-off for positivity. We carried out meta-analyses to estimate pooled sensitivity and specificity using a bivariate random-
effects model and estimated the models using a Bayesian approach. We determined accuracy of LF-LAM combined with sputum
microscopy or Xpert® MTB/RIF. In addition, we explored the influence of CD4 count on the accuracy estimates. We assessed the
quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Main results
We included 12 studies: six studies evaluated LF-LAM for TB diagnosis and six studies evaluated the test for TB screening. All studies
were cross-sectional or cohort studies. Studies for TB diagnosis were largely conducted among inpatients (median CD4 range 71 to
210 cells per µL) and studies for TB screening were largely conducted among outpatients (median CD4 range 127 to 437 cells per
µL). All studies were conducted in low- or middle-income countries. Only two studies for TB diagnosis (33%) and one study for TB
screening (17%) used a higher quality reference standard.
LF-LAM for TB diagnosis (grade 2 cut-off ): meta-analyses showed median pooled sensitivity and specificity (95% credible interval
(CrI)) of 45% (29% to 63%) and 92% (80% to 97%), (five studies, 2313 participants, 35% with TB, low quality evidence). The pooled
sensitivity of a combination of LF-LAM and sputum microscopy (either test positive) was 59% (47% to 70%), which represented a
19% (4% to 36%) increase over sputum microscopy alone, while the pooled specificity was 92% (73% to 97%), which represented a
6% (1% to 24%) decrease from sputum microscopy alone (four studies, 1876 participants, 38% with TB). The pooled sensitivity of
a combination of LF-LAM and sputum Xpert® MTB/RIF (either test positive) was 75% (61% to 87%) and represented a 13% (1%
to 37%) increase over Xpert® MTB/RIF alone. The pooled specificity was 93% (81% to 97%) and represented a 4% (1% to 16%)
decrease from Xpert® MTB/RIF alone (three studies, 909 participants, 36% with TB). Pooled sensitivity and specificity of LF-LAM
were 56% (41% to 70%) and 90% (81% to 95%) in participants with a CD4 count of less than or equal to 100 cells per µL (five
studies, 859 participants, 47% with TB) versus 26% (16% to 46%) and 92% (78% to 97%) in participants with a CD4 count greater
than 100 cells per µL (five studies, 1410 participants, 30% with TB).
LF-LAM for TB screening (grade 2 cut-off ): for individual studies, sensitivity estimates (95% CrI) were 44% (30% to 58%), 28%
(16% to 42%), and 0% (0% to 71%) and corresponding specificity estimates were 95% (92% to 97%), 94% (90% to 97%), and
95% (92% to 97%) (three studies, 1055 participants, 11% with TB, very low quality evidence). There were limited data for additional
analyses.
The main limitations of the review were the use of a lower quality reference standard in most included studies, and the small number
of studies and participants included in the analyses. The results should, therefore, be interpreted with caution.
Authors’ conclusions
We found that LF-LAM has low sensitivity to detect TB in adults living with HIV whether the test is used for diagnosis or screening.
For TB diagnosis, the combination of LF-LAM with sputum microscopy suggests an increase in sensitivity for TB compared to either
test alone, but with a decrease in specificity. In HIV-positive individuals with low CD4 counts who are seriously ill, LF-LAMmay help
with the diagnosis of TB.
P L A I N L A N G U A G E S U M M A R Y
The lateral flow urine lipoarabinomannan (LF-LAM) test for diagnosis of tuberculosis in people living with human immun-
odeficiency virus (HIV)
Background
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Tuberculosis (TB) is a common cause of death in people with human immunodeficiency virus (HIV) infection, but diagnosis is difficult,
and depends on testing for TB in the sputum and other sites, which may take weeks to give results. A rapid and accurate point-of-care
test could reduce delays in diagnosis, allow treatment to start promptly, and improve linkage between diagnosis and treatment.
Test evaluated by this review
The lateral flow urine lipoarabinomannan assay (LF-LAM, Alere DetermineT M TB LAM Ag, Alere Inc, Waltham, MA, USA) is a
commercially available point-of-care test for active TB (pulmonary and extrapulmonary TB). The test detects lipoarabinomannan
(LAM), a component of the bacterial cell walls, which is present in some people with active TB. The test is performed by placing urine
on one end of a test strip, with results appearing as a line (that is, a band) on the strip if TB is present. The test is simple, requires
no special equipment, and shows results in 25 minutes. During the period we conducted the review, the manufacturer issued new
recommendations for defining a positive test. We collected data based on both the original and the new recommendations
Objectives
We aimed to see how accurately LF-LAM diagnosed TB in people living with HIV with TB symptoms, and how accurately LF-LAM
diagnosed TB in people living with HIV being screened for TB whether or not they had TB symptoms.
Main results
We examined evidence up to 5 February 2015 and included 12 studies: six studies evaluated LF-LAM for TB diagnosis and six studies
evaluated the test for TB screening. All studies were conducted in low- or middle-income countries.
Quality of the evidence
We assessed quality by describing howparticipants were selected for the studies, details of the test and reference standards (the benchmark
test), and study flow and timing, using the standard QUADAS-2 approach. Few studies used multiple types of specimens for the
reference standard (higher quality standard) and most relied on sputum culture alone (lower quality standard), which may have affected
results.
What do the results mean?
In a population of 1000 HIV-positive individuals with TB symptoms, where 300 actually have TB, the test will correctly identify 135
people as having TB, but miss the remaining 165 people; for the 700 people who do not have TB, the test will correctly identify 644
people as not having TB, but will misclassify 56 as having TB.
The sensitivity of the test is higher in people living with HIV with low CD4 cell counts who are at risk of life-threatening illnesses. In
patients with a CD4 ≤ 100 cells per µL, LF-LAM sensitivity was 56% (41% to 70%) versus 26% (16% to 46%) in patients with a
CD4 count > 100 cells per µL.
If the test is used in screening HIV-positive people for TB, in a population of 1000 where 10 actually have TB, LF-LAM will correctly
identify none of the 10, or up to four of the 10; on the other hand, the test will miss six to 10 people with TB; in the remaining 990
who do not have TB, the test will correctly identify 931 to 941 people as not having TB while misclassifying 49 to 59 as having TB.
Limitations
The main limitations of the review were the use of a lower quality reference standard in most included studies, and small number of
studies and participants included in the analyses. The results should, therefore, be interpreted with caution.
Conclusions
In this Cochrane review, we found that LF-LAM, whether the test is used for diagnosis or screening, has low sensitivity to detect TB.
However, in HIV-positive people with low CD4 counts who are seriously ill, LF-LAM may help with the diagnosis of TB.
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B A C K G R O U N D
Target condition being diagnosed
Tuberculosis (TB) is caused by the mycobacteriumMycobacterium
tuberculosis and is transmitted through respiratory aerosols pro-
duced by people with active TB disease. Infection can be asymp-
tomatic for many years (referred to as latent TB infection), with
bacteria persisting in a viable but minimally replicating state. In a
small percentage of people, latent infectionmay reactivate at a later
time in a process that is commonly characterized by an increase
in the replication and number of bacteria, which leads to symp-
tomatic ’active TB disease’. TB predominantly affects the lungs
(pulmonary TB), but can also affect other parts of the body, such
as the brain or spine (extrapulmonary TB). Human immunode-
ficiency virus (HIV) infection is the most potent risk factor for
progression from latent TB infection to active TB disease (Kwan
2011). In this systematic review we are interested in the diagnosis
of active TB disease in people living with HIV.
Worldwide, in 2014, an estimated 1.2 million (12%) of the 9.6
million people who developed TB were HIV-positive; 74% of
these HIV-positive TB cases were in the African Region (WHO
Global Tuberculosis Report 2015). In 2014, TB killed 1.5 million
people. The number of people dying from HIV-associated TB
has been falling since 2004 (570,000 deaths); however in 2014 an
estimated 390,000 people died from HIV-associated TB (WHO
Global Tuberculosis Report 2015). TB is the leading cause of
death among people living with HIV, estimated to account for
around 33% of all HIV-related deaths globally (WHO Global
Tuberculosis Report 2015). However, a recent systematic review
of the prevalence of TB identified at autopsy suggests that, in re-
source-limited settings, TB is responsible for an even higher per-
centage (around 37% ) of all HIV-related deaths (Gupta 2015).
Most deaths from TB are preventable. It is estimated that 43 mil-
lion lives were saved between 2000 and 2014 through effective di-
agnosis and treatment (WHOGlobal Tuberculosis Report 2015).
TB and HIV are linked by geography and biology, and their in-
tersection has been called a “synergy from hell” (Bartlett 2007).
Geographically, HIV and TB are often concentrated in areas of
poverty with limited resources for diagnosis, treatment, and pre-
vention of TB. Much of the global burden of TB is concentrated
in sub-Saharan Africa, and HIV coinfection represents a major
driver of the epidemic in many areas. Linked by biology, each dis-
ease speeds the progress of the other. The risk of developing TB
is much higher in people living with HIV, estimated to be 20 to
37 times higher in HIV-positive individuals than in HIV-nega-
tive individuals (Getahun 2010). TB occurs early in the course of
HIV infection and shortens survival (Havlir 2008;Whalen 1995).
Many HIV-positive people in developing countries develop TB
as the first manifestation of AIDS (WHO Global Tuberculosis
Report 2015).
Signs and symptoms of TB in people living with HIV vary, which
makes it challenging to determine when to consider a diagnosis of
TB. Fever, weight loss, and fatigue are often the only symptoms of
HIV-associated TB and are non-specific. As a result, testing may
be delayed while other causes are evaluated. A cough for longer
than two weeks is a common distinguishing feature that prompts
diagnostic testing for TB in people who are HIV-negative, but is
present in less than a third of people with TB who are HIV posi-
tive (Cain 2010). Similarly, radiographic features of TB in people
living with HIV can be misleading or atypical. Whereas upper
lobe cavitary lesions are often seen in HIV-negative TB patients,
such lesions are less common in HIV-positive TB patients. In
comparison with HIV-negative people, HIV-positive people also
have higher rates of extrapulmonary TB or mycobacteraemia (TB
bloodstream infection). Extrapulmonary TB presentation varies
depending on the body site affected, and can mimic other dis-
eases such as cancer and bacterial and fungal infections. Identify-
ing people who warrant further testing for TB may therefore be
challenging in HIV-positive people.
Even when TB is suspected, current diagnostic approaches are in-
adequate. Sputum smear microscopy is the most widely utilized
TB diagnostic test worldwide. It has low sensitivity for TB (50%
to 60% on average) and identifies less than 50% of people with
HIV-related TB (Siddiqi 2003). Sputum smear microscopy does
not, by definition, identify smear-negative pulmonary or extrapul-
monary TB, which are more common in people who areHIV-pos-
itive than HIV-negative (Getahun 2007; Perkins 2007; Steingart
2006). Mycobacterial culture, the reference standard for TB, is
costly, requires significant laboratory infrastructure, takes weeks
to provide results, and is not widely available. Detection of extra-
pulmonary TB is dependent on intensive evaluation of sites of dis-
ease and culture of clinical specimens other than sputum, in con-
junction with clinical and radiographic evaluations. Hence, many
people with TB remain undiagnosed if co-infected with HIV.
Recently, a new test has become available for TB detection. The
Xpert® MTB/RIF assay (Cepheid, Sunnyvale, USA) is a fully
automated, nucleic acid amplification test (NAAT) for TB and
drug-resistant TB and is endorsed by the World Health Organi-
zation (WHO) (WHO Xpert® Policy Update 2013). A recent
Cochrane Review found that Xpert®MTB/RIF was sensitive and
specific for both TB detection and rifampicin resistance detection
and, compared with smear microscopy, substantially increased TB
detection among culture-confirmed cases (Steingart 2014). Al-
though sputum testing with Xpert® MTB/RIF has high sensitiv-
ity for smear-positive pulmonary TB (98%), sensitivity is lower
for smear-negative pulmonary TB (67%) (Steingart 2014). This
finding has bearing for HIV-associated TB where smear-negative
TB and extrapulmonary TB are disproportionately higher.
Index test(s)
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The lateral flow urine lipoarabinomannan assay (LF-LAM) is a
commercially available point-of-care test for active TB (Alere De-
termineT M TBLAMAg, Alere Inc,Waltham,MA,USA). The test
detects lipoarabinomannan (LAM), a lipopolysaccharide present
in mycobacterial cell walls, which is released from metabolically
active or degenerating bacterial cells and appears to be present only
in people with active TB disease.
LAM is detectable in the urine of people with active TB (Peter
2010). Urine-based testing has advantages over sputum-based test-
ing because urine is easy to collect and store, and lacks the infec-
tion control risks associated with sputum collection. Several stud-
ies (Dheda 2010; Lawn 2009; Lawn 2012a; Lawn 2012b; Peter
2012; Shah 2009) and a meta-analysis of an earlier generation
LAM-ELISA test (Minion 2011) have found that the accuracy of
urinary LAM detection may be improved among people living
with HIV with advanced immunosuppression. Several hypothe-
ses may explain the higher sensitivity of urine LAM detection in
HIV-positive people including higher bacillary burden and anti-
gen load, greater likelihood of genitourinary tract TB involve-
ment, and greater glomerular permeability to allow increased anti-
gen levels in urine (Minion 2011).
LF-LAM is performed manually by applying 60 µL of urine to
the DetermineT M TB LAM Ag test strip and incubating at room
temperature for 25 minutes (Alere 2014). The strip is then in-
spected by eye. The intensity of any visible band on the test strip
is graded by comparing it with the intensities of the bands on a
manufacturer-supplied reference card. Prior to January 2014, this
reference card included five bands (grade 1 representing a very low
intensity band to grade 5 representing a high/dark intensity band).
Some studies prior to January 2014 utilized grade 1 as the thresh-
old for test positivity, while other studies utilized grade 2 as the
positivity threshold. After January 2014, the manufacturer revised
the reference card to have four reference bands, such that the band
intensity for the new grade 1 corresponded to the band intensity
for the previous grade 2. Under manufacturer recommendations
(using the new reference card), bands that are grade 1 or higher
are considered positive (Figure 1).
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Figure 1. (A) Alere DetermineTM TB LAM Ag tests. To the sample pad (white pad marked by the arrow
symbols) 60 µL of urine is applied and visualized bands are read 25 minutes later. (B) Reference card
accompanying test strips to ’grade’ the test result and determine positivity (33). Copyright © [2014] [Alere
Inc]: reproduced with permission.
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Clinical pathway
The WHO guidelines on intensified case-finding in people living
with HIV recommend that, in resource-constrained settings, peo-
ple living with HIV who report “any one of the symptoms of cur-
rent cough, fever, weight loss, or night sweats should be evaluated
for TB and other diseases” (Getahun 2011; WHO Tuberculosis
Screening 2013). Further diagnostic work-up for people with a
positive symptom screen includes sputum smear microscopy, and,
in some settings, sputum Xpert® MTB/RIF or mycobacterial
culture (WHO Tuberculosis Screening 2013). Importantly, some
HIV-positive people may have difficulty producing any sputum
at all, or may have extrapulmonary forms of TB. When extrapul-
monary TB is suspected, it is standard practice to obtain “appro-
priate specimens from the suspected sites of involvement for mi-
croscopy, culture, and histopathological examination” (TB CARE
I 2014). Evaluation for extrapulmonary TB often requires invasive
diagnostic procedures that may have low yield even in people with
advanced disease.
People living with HIV are at increased risk of TB but may be
asymptomatic. As such, urine LF-LAMcould also be used to screen
for TB in people living with HIV, irrespective of symptoms. The
WHO defines screening for active TB as “the systematic identi-
fication of people with suspected active TB, in a predetermined
target group, using tests, examinations or other procedures that
can be rapidly applied” (WHO Tuberculosis Screening 2013).
LF-LAM could be used as either (1) a replacement test for an
existing test (that is, sputum smear microscopy or sputum Xpert®
MTB/RIF), or (2) a parallel test, i.e. a ’new test’ intended to be
used concurrently in combination with an existing test.
Alternative test(s)
We evaluated the performance of LF-LAM in comparison to or in
combination with sputum smear microscopy or sputum Xpert®
MTB/RIF. Sputum smear microscopy involves the microscopic
evaluation of sputum specimens using stains for acid-fast bacilli
that identify mycobacteria (but do not distinguish M. tuberculosis
from nontuberculous mycobacteria). Xpert®MTB/RIF is a semi-
automated integrated specimen processing and NAAT for detec-
tion of TB and rifampicin resistance.
Rationale
New tests and strategies for detection of TB are urgently needed to
curb the ongoing HIV-TB co-epidemic. Among the key priorities
identified by the WHO, healthcare providers, patients, and advo-
cacy groups is development of a point-of-care test for TB (Batz
2011; Pai 2012; Weyer 2011). LF-LAM, if sufficiently accurate,
would satisfy many of the established minimum specifications for
a point-of-care test for TB (Appendix 1; Batz 2011). Furthermore,
the test could provide obvious benefits for HIV-positive people
who suffer the highest morbidity and mortality, by earlier detec-
tion of pulmonary TB that may be missed by sputum smear mi-
croscopy and sputum Xpert®MTB/RIF and extrapulmonary TB
that may be missed by sputum-based testing. The draft of this
systematic review informed the WHO policy recommendations
on the use of LF-LAM for the diagnosis and screening of active
TB in people living with HIV (WHO Lipoarabinomannan Policy
Guidance 2015).
O B J E C T I V E S
Primary objectives
• To assess the accuracy of lateral flow urine
lipoarabinomannan assay (LF-LAM) for the diagnosis of active
tuberculosis (TB) disease in HIV-positive adults who have signs
and symptoms suggestive of TB.
• To assess the accuracy of the LF-LAM as a screening test for
active TB disease in HIV-positive adults irrespective of signs and
symptoms suggestive of TB.
Secondary objectives
• To compare the diagnostic accuracy of LF-LAM and
existing tests, sputum smear microscopy or sputum Xpert®
MTB/RIF, as well as determine the diagnostic accuracy of LF-
LAM when added to existing tests.
• To investigate heterogeneity of test accuracy in the included
studies. Possible sources of heterogeneity include CD4 count and
clinical setting (inpatient versus outpatient setting).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included primary studies that evaluated the accuracy of LF-
LAM for diagnosis of or screening for active TB in people living
with HIV and compared the index test with a defined reference
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standard. We also included studies that assessed the diagnostic ac-
curacy of one of the alternative tests (sputum microscopy or spu-
tum Xpert® MTB/RIF) in addition to LF-LAM. Eligible study
types included randomized controlled trials, cross-sectional stud-
ies, and observational cohort studies. We included abstracts with
sufficient data. We excluded case-control studies.
We included studies that provided data from which we could ex-
tract true positive (TP), false positive (FP), true negative (TN),
and false negative (FN) values, based on one of the reference stan-
dards defined below.
Participants
Participants were adults (15 years and older is considered ’adult’
for purpose of TB surveillance) and who were HIV positive. We
included participants in whom there was a suspicion of TB based
on the presence of signs and symptoms compatiblewithTB, aswell
as participants who may or may not have had signs and symptoms
compatible with TB and had not been previously evaluated for
TB. Signs and symptoms of TB include cough, fever, weight loss,
and night sweats.
Index tests
The index test was Alere DetermineT M TB LAM Ag test (LF-
LAM, Alere Inc., Waltham, MA, USA), the only commercial lat-
eral flow urine LAM assay available as of December 2015.We eval-
uated the test at two different cut-off values for positivity (grade
1 and grade 2) based on the original manufacturer reference card.
Grade 2 (corresponding to grade 1 on the newmanufacturer refer-
ence card) is the currently recommended threshold for positivity.
Target conditions
The target condition was active TB disease, which includes pul-
monary and extrapulmonary TB.
Reference standards
We required studies to diagnose TB using at least one of the fol-
lowing two reference standards.
• Microbiological reference standard:
◦ we defined ’TB’ as a positive M. tuberculosis culture or
nucleic acid amplification test (NAAT);
◦ we defined ’not TB’ as a negative M. tuberculosis
culture and NAAT (if performed).
• Composite reference standard that included M. tuberculosis
culture together with at least one of the following components:
NAAT, smear, or clinical findings:
◦ we defined ’TB’ as (1) a positive culture, or (2) a
positive NAAT, or (3) a positive smear, or (4) a clinical decision
to start TB treatment, and, after at least one month of follow-up,
the participant was diagnosed as having TB;
◦ we defined ’not TB’ as a negative culture and NAAT
(if performed), no TB treatment given, and resolution of signs
and symptoms at follow-up.
NAATs included: Enhanced Amplified Mycobacterium Tubercu-
losis Direct Test (E-MTD, Gen-Probe, San Diego, USA); Am-
plicor Mycobacterium tuberculosis Test (Amplicor, Roche Diag-
nostics, Basel, Switzerland); COBAS® TaqMan® MTB Test
(Roche Diagnostics); GenoTypeMTBDRplus (HAIN Lifescieces,
Nehren, Germany); and Xpert® MTB/RIF assay (Cepheid, Sun-
nyvale, USA).
For a microbiological reference standard, we considered a higher
quality reference standard to be one in which two or more spec-
imen types were evaluated for TB diagnosis and a lower quality
reference standard to be one in which only one specimen type was
evaluated for TB diagnosis. For a composite reference standard, we
did not require all components to be provided on all participants.
Of note, we excluded sputum smear from a composite reference
standard and sputum Xpert® MTB/RIF from both a microbio-
logical and a composite reference standard for the purpose of per-
forming analyses of LF-LAM in combination with either sputum
smear or sputum Xpert® MTB/RIF.
We excluded participants as ’unclassifiable’ if we could not classify
them as either ’TB’ or ’not TB’ based on these reference standard
definitions.
We consider that there are strengths and limitations to each ref-
erence standard. A microbiological reference standard, primarily
culture, is considered the best reference standard. We expected all
studies to obtain sputum specimens and some studies to obtain
additional specimens for culture. However, the primary concern
with relying on sputumculture alone is that peoplewithTBdisease
may bemissed for the following reasons: HIV-positive people may
not be able to provide sputum specimens of sufficient quality; spu-
tum bacillary load is typically low in people living with HIV; and
a substantial proportion of people with HIV-associated TB can-
not produce sputum at all (Lawn 2013a) or have extrapulmonary
TB without pulmonary TB. This means that index test TPs may
be misclassified as FPs by sputum culture. Therefore, when eval-
uating LF-LAM with respect to sputum culture, the number of
FPs (classified as positive by the index test and negative by the
reference test) may be increased and LF-LAM specificity may be
underestimated (Lawn 2015). This misclassification may also lead
to underestimation of sensitivity. Increasing the sensitivity of the
reference standard by evaluating multiple specimens, including
evaluating specimens from sites of disease for extrapulmonary TB,
may reduce the number of cases of TB disease incorrectly classified
as ’not TB’ by culture.
In contrast, a composite reference standard that includes micro-
biological or clinical components may correctly classify index test
results as TPs (instead of as FPs with respect to culture), espe-
cially in people with paucibacillary disease in whom culture may
be negative. However, because of the uncertainties that surround a
clinical diagnosis of TB, a reference standard that uses clinical TB
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(in culture-negative people) is considered a lower quality reference
standard and may incorrectly classify people without TB as having
TB.
Search methods for identification of studies
Electronic searches
To identify all relevant studies, on 5 February 2015, Vittoria
Lutje (VL), the Information Specialist for the Cochrane Infectious
Diseases Group (CIDG), performed literature searches without
language restrictions in the following databases using the search
terms we have reported in Appendix 2: the Cochrane Infectious
Diseases Group Specialized Register; MEDLINE (PubMed, from
1966); EMBASE (OVID, from 1980); Science Citation Index Ex-
panded (SCI-EXPANDED, from 1900), Conference Proceedings
Citation Index- Science (CPCI-S, from 1900), and BIOSIS Pre-
views (from 1926), all three using the Web of Science platform;
MEDION(http:/www.mediondatabase.nl/); LILACS (BIREME,
from 1982); and SCOPUS (from 1995). She also searched the
metaRegister of ControlledTrials (mRCT) and the search portal of
the WHO International Clinical Trials Registry Platform (WHO
ICTRP, www.who.int/trialsearch) to identify ongoing trials, and
ProQuest Dissertations & Theses A&l (from 1861) to identify
relevant dissertations.
Searching other resources
We examined reference lists of relevant reviews and studies,
searched the WHO websites, and contacted Alere Inc. and re-
searchers in the field to identify ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (MS and CH) first independently examined
all titles and abstracts identified from the electronic search to de-
termine potentially eligible studies. We then obtained the full-
text articles of these potentially eligible studies and the same two
review authors independently assessed inclusion based on prede-
fined inclusion and exclusion criteria. We resolved disagreements
through discussion and, if necessary, consulted a third review au-
thor (KRS).
Data extraction and management
We developed a standardized data extraction form and piloted the
form on two of the included studies. Based upon the results of the
pilot, we finalized the form. Then two review authors (MS and
CH) independently extracted data from each included study on
the following characteristics.
• Author, publication year, study design, country(ies), clinical
setting (outpatient or inpatient).
• Participants: age, gender, CD4 count, clinical status
(asymptomatic, symptomatic).
• Quality Assessment of Diagnostic Accuracy Studies-2
(QUADAS-2) items.
• Cut-off used for determining a positive index test result,
grade 1 or 2.
• Reference standard(s).
• Number of true positive (TP), false negative (FN), false
positive (FP), and true negative (TN) values and for the index
test, sputum microscopy, and sputum Xpert® MTB/RIF.
• Missing or unavailable test results.
• Intra-reader and inter-reader variability.
• Participant health outcomes: time to treatment initiation
(time from specimen collection until time the participant starts
treatment), morbidity, and mortality.
We assigned country income status (high-income, or low- and
middle-income) as classified by theWorld Bank List of Economies
(World Bank 2014).
For one study that reported results using the new reference card (
LaCourse 2015), we converted results to the originalmanufacturer
scale to allow consistent comparisons.
For a composite reference standard, we found that these data were
largely unavailable in the publications and interpreted differently
by study authors. Therefore, we sent our definition of a composite
reference standard to study authors and requested that they provide
TP, FP, FN, and TP values using our definition. Furthermore,
we excluded participants assigned to ’TB’ and ’not TB’ if study
authors considered clinical findings alone and there was not at least
one month of follow-up. Participants may be lost during follow-
up for unknown reasons or death. We excluded these participants
because we could not accurately classify their TB status.
If a study applied an approach of testing all participants in the
inpatient setting, we assigned the purpose of testing as ’diagno-
sis’, rather than screening. We made this assignment because we
considered it likely that most inpatients had TB symptoms even
though they were not enrolled in the study on the basis of specific
TB symptoms.
We contacted study authors for missing data and clarifications and
entered all data into Microsoft® Excel.
The data extraction form is in Appendix 3.
Assessment of methodological quality
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We used the QUADAS-2 tool to assess the quality of the included
studies (Whiting 2011; Appendix 4). QUADAS-2 consists of four
domains: patient selection, index test, reference standard, and flow
and timing (flow and timing domain includes differential verifica-
tion of TB status for study participants). We assessed all domains
for risk of bias and the first three domains for concerns regarding
applicability. As recommended, we first developed guidance on
how to appraise each question and interpreted this information
tailored to this review. Then, one review author (MS) piloted the
tool with two of the included studies. Based on the experience
we gained from the pilot, we finalized the tool. Two review au-
thors (MS and CH) independently completed QUADAS-2. We
resolved disagreements through discussion or consulted a third re-
view author (KRS). We presented the results of the quality assess-
ment in the text, the ’Characteristics of included studies’ table,
and graphs.
Statistical analysis and data synthesis
We performed descriptive analyses of the characteristics of the in-
cluded studies using Stata 13 (StataCorp 2011), and presented
key study characteristics in the ’Characteristics of included studies’
table. We used the number of TPs, FPs, FNs, and TNs to cal-
culate the individual study estimates of sensitivity and specificity
and their 95% confidence intervals (CI). We presented individual
study results graphically by plotting the estimates of sensitivity and
specificity (and their 95% CIs) in forest plots and receiver operat-
ing characteristic (ROC) space using Review Manager (RevMan)
(Review Manager). We presented the results from all studies using
the original manufacturer scale for test interpretation, with band
intensities graded on a scale of 1 to 5 (from lightest to darkest).
The newer manufacturer reference card is graded on a scale of 1
to 4, with lightest band intensity (grade 1) corresponding to the
prior grade 2. To allow consistent comparisons, we converted re-
sults from studies utilizing the newer manufacturer reference card
to the original manufacturer scale (that is, ’grade 1’ results using
the new scale are treated in this review as ’grade 2’).
Asmentioned above, during the period in which we conducted the
review, the manufacturer issued new recommendations for defin-
ing a positive test. Although, we determined accuracy estimates
separately at the original (grade 1) and currently recommended
(grade 2) cut-offs and present the estimates in forest plots and ta-
bles, we focused our attention in the main text on the diagnostic
accuracy of grade 2.
We used a microbiological reference standard for most analyses.
We grouped studies according to the purpose of testing, diagnosis,
or screening. Then, when we considered the studies to be compa-
rable, we carried out meta-analyses to estimate LF-LAM pooled
sensitivity and specificity with a bivariate random-effects model
(Chu 2009; Reitsma 2005). This approach allowed us to calcu-
late pooled sensitivity and specificity while dealing with potential
sources of variation caused by: (1) imprecision of sensitivity and
specificity estimates within individual studies; (2) correlation be-
tween sensitivity and specificity across studies; and (3) variation
in sensitivity and specificity between studies.
We compared the sensitivity and specificity of LF-LAMwhen per-
formed alone, with the sensitivity and specificity of sputum smear
microscopy or sputum Xpert® MTB/RIF in direct comparisons
inwhich both tests were evaluated in the same participants.We ad-
ditionally determined the value of LF-LAMwhen used as a parallel
test in combination with sputum microscopy or sputum Xpert®
MTB/RIF based on data from studies that reported results of LF-
LAM and either or both of these tests. To illustrate, for LF-LAM
used as a parallel test, we determined the increase in sensitivity
of a combination of LF-LAM and (1) sputum microscopy or (2)
sputum Xpert® MTB/RIF compared with the sensitivity of spu-
tum smear microscopy or sputum Xpert® MTB/RIF alone. We
determined the potential decrease in specificity of a combination
of LF-LAM and (1) sputum microscopy or (2) sputum Xpert®
MTB/RIF compared with the specificity of sputum microscopy
or sputum Xpert® MTB/RIF alone. In these meta-analyses, we
accounted for conditional dependence between the accuracy esti-
mates of LF-LAM and the comparator test (sputum microscopy,
or sputum Xpert®MTB/RIF, or a combination of LF-LAM with
sputum microscopy or sputum Xpert® MTB/RIF) by extending
the standard bivariate model to include separate study-level covari-
ance terms (Novielli 2013; Vacek 1985) between the sensitivities
of the two tests, for example, Xpert® MTB/RIF and LF-LAM.
We did not add covariance terms between the specificities, which
were generally very high for all tests.
We estimated all models using a Bayesian approach implemented
using WinBUGS (Lunn 2000). Under the Bayesian approach, all
unknown parameters must be provided a prior distribution that
defines the range of possible values of the parameter and the weight
of each of those values, based on information external to the data.
In order to let the observed data dominate the final results, we
chose to use low-information prior distributions. We defined prior
distributions on the log-odds scale over the pooled sensitivity and
specificity parameters, their corresponding between-study stan-
dard deviations (SDs) and the correlation between the sensitivi-
ties and specificities across studies. For the pooled log odds of the
sensitivity or log odds of the specificity, we used a normal prior
distribution with mean 0 and a wide variance of 4 (or a precision
of 0.25). This corresponds to a roughly uniform distribution over
the pooled sensitivity and pooled specificity on the probability
scale. For the between-study precision we used a gamma distri-
bution with a shape parameter of two and rate parameter of 0.5.
This corresponds to a 95% prior credible interval (CrI) for the
between-study SD in the log odds of sensitivity or log odds of
specificity ranging from roughly 0.29 to 1.44, corresponding to
moderate to high values of between-study heterogeneity. Covari-
ance terms followed a uniform prior distribution whose upper and
lower limits were determined by the sensitivity of the two tests.We
have summarized the models we used (including the prior distri-
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butions) and the WinBUGS programs we used to estimate them
in Appendix 5.
We had two instances where there were only three included studies
in the meta-analysis, which led the model to be just identified
and highly dependent on the prior information. Nonetheless, we
chose not to simplify the bivariate to a univariate model in these
cases as we wished to estimate the incremental value of one test
over another by taking the difference between parameters in these
two meta-analysis models. Bivariate models are preferable for such
comparisons Trikalinos 2014.
Meta-analysis models based on few studies are sensitive to the
choice of prior distributions, particularly the prior distributions
over the between-study SD parameters. To study the sensitivity of
all our results to the choice of prior distributions given above, we
considered alternative prior distributions that were less informa-
tive, which allowed a wider range of possible values. We increased
the variance of the normal distributions over the pooled log odds
of the sensitivity or specificity to 100. We used a uniform prior
distribution ranging from zero to three over the between-study
SD on the log odds scale. We found that the pooled estimates
remained roughly the same with these alternative priors, though
the posterior CrIs were wider, as expected.
We combined information from the prior distribution with the
likelihood of the observed data, in accordance with Bayes’ theo-
rem in the WinBUGS program, which resulted in a sample from
the posterior distribution of each unknown parameter. Using this
sample, we calculated various descriptive statistics of interest. We
estimated the median pooled sensitivity and specificity and their
95% CrI. The median or the 50% quantile is the value below
which 50% of the posterior sample lies. We reported the median
because the posterior distributions of some parameters may be
skewed and the median would be considered a better point esti-
mate of the unknown parameter than the mean in such cases. The
95% CrI is the Bayesian equivalent of the classical (frequentist)
95% CI (we indicated 95% CI for individual study estimates and
95% CrI for pooled study estimates as appropriate). The 95%
CrI may be interpreted as an interval that has a 95% probability
of capturing the true value of the unknown parameter given the
observed data and the prior information.
To compare tests, we first defined the difference in the pooled
sensitivity and the difference in the pooled specificity. Once the
posterior distribution of the difference in sensitivities between two
tests is available, we can estimate the probability that this difference
exceeds zero.
Approach to uninterpretable LF-LAM results
We excluded uninterpretable test results from the analyses for de-
termination of sensitivity and specificity. We summarized unin-
terpretable results as reported by the included studies.
Investigations of heterogeneity
Initially, we investigated heterogeneity through visual examination
of forest plots of sensitivities and specificities and through visual
examination of the ROC plot of the raw data. When data were
sufficient, we performed subgroup analyses with the following
categorical covariates: CD4 count (> 200 versus ≤ 200 cells per
µL; > 100 versus ≤ 100 cells per µL ; and > 50 versus ≤ 50
cells per µL) and clinical setting (inpatient versus outpatient). We
generated the plots depicting the pooled results within CD4 count
categories using R (R Statistical Computing 2015).
Sensitivity analyses
For our primary analysis using a microbiological reference stan-
dard, we performed sensitivity analyses by limiting inclusion in
the meta-analysis to the following.
• Studies that avoided inappropriate exclusions, for example,
studies that included participants who could not produce
sputum. For this analysis we included studies that we scored as
’yes’ for the QUADAS-2 question, “Did the study avoid
inappropriate exclusions?” (low risk of bias for participant
selection).
• Studies in which two or more specimen types were
evaluated for TB diagnosis. For this analysis, we included studies
that we scored as ‘yes’ for the QUADAS-2 question, “Is the
reference standard likely to correctly classify the target condition”
(low risk of bias for the reference standard).
Additional analyses
We extracted data on intra- and inter-reader variability. Within
the included studies, we recorded whether there was an association
between LF-LAM results and disease severity or mortality.We had
intended to describe the effect of LF-LAM implementation (that
is, LF-LAM used versus LF-LAM not used) on patient important
outcomes; however, there were limited data to do this.
Assessment of reporting bias
We did not carry out a formal assessment of publication bias us-
ing methods such as funnel plots or regression tests because such
techniques have not been helpful for diagnostic test accuracy stud-
ies (Macaskill 2010). However, with our extensive outreach to re-
searchers, we believe reporting bias to be minimal.
Assessment of the quality of the evidence
We assessed the quality of the evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (Schünemann 2008; Schünemann 2013). As
recommended, we rated the quality of evidence as either high (not
downgraded), moderate (downgraded by one level), low (down-
graded by two levels), or very low (downgraded by more than two
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levels) based on five domains: risk of bias, indirectness, inconsis-
tency, imprecision, and publication bias. For each outcome, the
quality of evidence started as high when there were high qual-
ity observational studies (cross-sectional or cohort studies) that
enrolled participants with diagnostic uncertainty. If we found a
reason for downgrading, we used our judgement to classify the
reason as either serious (downgraded by one level) or very serious
(downgraded by two levels).
Four review authors (MS, CH, ND, and KRS) discussed judg-
ments and applied GRADE in the following way:
• Risk of bias: we used QUADAS-2 to assess risk of bias.
• Indirectness: we considered indirectness from the
perspective of test accuracy. We used QUADAS-2 for concerns
of applicability and looked for important differences between the
populations studied (for example, in the spectrum of disease),
the setting, and the review questions.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity estimates.
We carried out pre-specified analyses to investigate potential
sources of heterogeneity and did not downgrade when we felt we
could explain inconsistency in the accuracy estimates.
• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CrI, and asked ourselves, “Would we make a
different decision if the lower or upper boundary of the CrI
represented the truth?” In addition, we worked out projected
ranges for TP, FN, TN, and FP for a given prevalence of TB and
made judgements on imprecision from these calculations.
• Publication bias: we rated publication bias as undetected
(not serious) for several reasons including the comprehensiveness
of the literature search, communication with Alere, the test
manufacturer, and extensive outreach to TB researchers to
identify studies.
R E S U L T S
Results of the search
Our search yielded 2409 records. We identified four additional
studies through contact with experts. After we removed duplicates,
we identified 910 records. We excluded 842 records based on a re-
view of title, or abstract, or both. We retrieved 68 full-text articles,
of which we excluded 55 studies for the following reasons: index
test not evaluated (33 studies); insufficient data (lack of sufficient
data to derive 2 x 2 tables or assess test performance in participants
with and without TB) or duplicate data (15 studies); and editori-
als, reviews, or comments (seven studies). In addition, we excluded
one ongoing study (Grant ongoing) which remained unpublished
as of December 2015. Therefore, we included 12 unique stud-
ies in this review (Andrews 2014; Balcha 2014; Bjerrum 2015;
Drain 2014b; Drain 2014a; Drain 2014c; LaCourse 2015; Lawn
2012a; Lawn 2014a; Nakiyingi 2014; Peter 2012a; Peter 2015).
We listed the excluded studies and reasons for their exclusion in
the ’Characteristics of excluded studies’ section. Figure 2 shows
the flow of studies in the review.
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Figure 2. Study flow diagram.
All included studies were performed in low- or middle-income
countries. We noted substantial differences in the included stud-
ies for the following characteristics: purpose for which lateral flow
urine lipoarabinomannan assay (LF-LAM) was applied (diagno-
sis versus screening); setting (inpatient versus outpatient); thresh-
old used to define LF-LAM positivity (grade 1 versus grade 2);
inclusion and exclusion of participants based on whether or not
they could produce sputum and whether or not they received an
evaluation for extrapulmonary TB; and type of reference stan-
dard (microbiological versus composite reference standard) (see
the ’Characteristics of included studies’ section).
Methodological quality of included studies
For the purpose of TB diagnosis, six studies contributed data
(Figure 3). In the patient selection domain, we considered two
studies (33%) to be at high risk of bias because: (1) the study
excluded all smear-positive participants (Drain 2014c); (2) the
study excluded participants who were unable to expectorate spu-
tum (Peter 2015). All studies were cross-sectional or cohort stud-
ies. Regarding applicability (i.e. Are there concerns that the in-
cluded patients do not match the review question?), we judged
that all studies included the appropriate participants and settings.
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Figure 3. LF-LAM for TB diagnosis. ’Risk of bias’ and applicability concerns summary: review authors’
judgements about each domain for each included study.
In the index test domain, we considered all studies to be at low risk
of bias, as all studies used LF-LAM, pre-specified the grade used
for positivity, and interpreted the test without knowledge of the
results of the reference standard. In addition, we considered the
conduct and interpretation of the index test to be of low concern
for applicability in all included studies.
In the reference standard domain, we considered four studies
(66%) to be at high risk of bias because: (1) the study only con-
ductedmycobacterial blood culture as the reference standard with-
out testing of respiratory specimens (Andrews 2014); (2) the stud-
ies did not include testing of extrapulmonary specimens (Drain
2014c; Peter 2015); and (3) health providers selected the sites for
testing based on their own clinical suspicion (Peter 2012a). In
terms of applicability, we deemed one study at high concern be-
cause of a lack of study directed testing (Peter 2012a). In this study
health providers selected the sites for testing based on their own
clinical suspicion, and it was unclear if their choice of reference
standard would correctly classify TB.
In the flow and timing domain, we considered one study (17%)
to be at high risk of bias because not all participants received the
same reference standard (Peter 2012a). We judged the remaining
studies to be at low risk of bias because all participants received
the index test and the same reference standard and no participants
were excluded from the 2 x 2 table.
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For the purpose of TB screening, six studies contributed data
(Figure 4). In the patient selection domain, we considered two
studies (33%) to be at high risk of bias because these studies ex-
cluded participants who were unable to expectorate sputum and
made no attempts at sputum induction (Balcha 2014; Bjerrum
2015). All studies were cross-sectional or cohort studies. Regard-
ing applicability, we judged that all studies (100%) included the
appropriate participants and settings.
Figure 4. LF-LAM for TB screening. ’Risk of bias’ and applicability concerns summary: review authors’
judgements about each domain for each included study.
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In the index test domain, we considered all studies at low risk
of bias as all studies used LF-LAM, pre-specified the grade used
for positivity, and interpreted the test without knowledge of the
results of the reference standard. We considered the test conduct
and interpretation in all studies (100%) to be applicable.
In the reference standard domain,we consideredfive studies (83%)
to be at high risk of bias because these studies did not conduct
microbiological testing on extrapulmonary specimens (Bjerrum
2015; Drain 2014a; Drain 2014b; LaCourse 2015; Lawn 2012a).
We judged these studies to be of low concern in terms of applica-
bility.
In the flow and timing domain, we considered one study (17%)
to be at high risk of bias because not all participants received the
same reference standard (Balcha 2014).We considered five studies
(83%) to be of low risk of bias because all participants received
the index test and the same reference standard and no participants
were excluded from the 2 x 2 table.
Findings
We present pooled sensitivity and specificity of LF-LAM (grade 1
and grade 2) for TB diagnosis in Table 1.
LF-LAM for TB diagnosis among participants with
signs or symptoms of TB
Six studies evaluated the accuracy of LF-LAM for TB diagnosis in
participants with signs and symptoms suggestive of TB (Andrews
2014; Drain 2014c; Lawn 2014a; Nakiyingi 2014; Peter 2012a;
Peter 2015). All studies provided data at grade 1 (2402 partici-
pants; 876with TB) and five (83%) provided data at grade 2 (2313
participants; 819 with TB). The median CD4 cell count in these
studies ranged from 71 to 210 cells per µL. Three studies (50%)
were conducted exclusively in an inpatient setting (Andrews 2014;
Lawn 2014a; Peter 2012a), one study was conducted exclusively
in an outpatient setting (Peter 2015), and two studies were con-
ducted in both inpatient and outpatient settings (Nakiyingi 2014;
Drain 2014c).
LF-LAM (grade 2), microbiological reference standard
In the analysis of LF-LAM (grade 2) for TB diagnosis with respect
to a microbiological reference standard, we included five studies
that included 2313 HIV-positive participants, 819 (35%) with
TB (Andrews 2014; Lawn 2014a; Nakiyingi 2014; Peter 2012a;
Peter 2015). Sensitivity estimates ranged from 23% to 84%, and
specificity estimates from 75% to 99% (Figure 5). Sensitivity was
lowest in Peter 2015. Differences between this study and the other
studies in this analysis included setting (outpatient only), focus
on pulmonary TB (no extrapulmonary samples were taken), and
exclusion of participants unable to produce sputum. The pooled
sensitivity and specificity (95% CrI) were 45% (29% to 63%) and
92% (80% to 97%).
Figure 5. Forest plots of LF-LAM (Grade 1 and 2) sensitivity and specificity for TB against a microbiological
reference standard (TB diagnosis). TP = True Positive; FP = False Positive; FN = False Negative; TN = True
Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows
the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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LF-LAM (grade 1), microbiological reference standard
In the analysis of LF-LAM (grade 1) for TB diagnosis, with respect
to a microbiological reference standard, we included six studies in-
volving 2402HIV-positive patients, 876 (36%)withTB (Andrews
2014; Drain 2014c; Lawn 2014a; Nakiyingi 2014; Peter 2012a;
Peter 2015). Sensitivity estimates ranged from 38% to 100% and
specificity estimates, from 50% to 95% (Figure 5). Sensitivity was
lowest in Peter 2015 as discussed above for LF-LAM (grade 2).
Specificity was lowest in Andrews 2014, which was notable for
the lack of microbiological testing beyond mycobacterial blood
culture and may have led to misclassification of some participants
with TB as ‘not TB’. The pooled sensitivity and specificity (95%
CrI) were 59% (43% to 77%) and 78% (64% to 88%).
LF-LAM (grade 2), composite reference standard
Three studies evaluated LF-LAM (grade 2) for TB diagnosis, with
respect to a composite reference standard (Nakiyingi 2014; Peter
2012a; Peter 2015). In these studies, we considered 270 partici-
pants to be ‘unclassifiable’ (54 LF-LAM-positive; 216 LF-LAM-
negative). Sensitivity estimates ranged from 11% to 45% and
specificity estimates ranged from 96% to 98% (Figure 6).
Figure 6. Forest plots of LF-LAM (grade 2) sensitivity and specificity for TB against a composite reference
standard (TB diagnosis). TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative.
Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the
estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
LF-LAM (grade 2) and existing tests
LF-LAM versus sputum microscopy
Four studies including 1876 participants (708 (38%) with TB),
directly compared LF-LAM and sputum microscopy in the same
patients (Lawn 2014a; Nakiyingi 2014; Peter 2012a; Peter 2015).
(We classified participants unable to produce sputum as negative
by sputum testing). Pooled sensitivities were similar, 38% (34%
to 42%) for LF-LAM and 40% (27% to 54%) for sputum mi-
croscopy. Pooled specificity was 95% (94% to 97%) for LF-LAM
and 98% (93% to 100%) for sputum microscopy (Figure 7).
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Figure 7. Accuracy of smear microscopy (black circle) and smear microscopy in combination with LF-LAM
(Grade 2) (blue circle) plotted in receiver operating characteristic (ROC) space. The dashed lines are only for
illustration to show how sensitivity and specificity changed with the addition of the LF-LAM test.
LF-LAM in combination with sputum microscopy
The pooled sensitivity of a combination of LF-LAM and sputum
microscopy (either test positive) was 59% (47% to 70%), rep-
resenting a 19% (4% to 36%) increase over sputum microscopy
alone, while the pooled specificity was 92% (73% to 97%), rep-
resenting a 6% (1% to 24%) decrease from sputum microscopy
alone (Figure 7).
LF-LAM versus sputum Xpert® MTB/RIF
Three studies including 909 participants (327 (36%) with TB),
directly compared LF-LAM and sputum Xpert® MTB/RIF in
the same patients (Lawn 2014a; Nakiyingi 2014; Peter 2015).
(We classified participants unable to produce sputum as negative
by sputum testing). The pooled sensitivity of LF-LAM was 36%
(31% to 42%), lower than the pooled sensitivity of Xpert®MTB/
RIF of 61% (39% to 77%). Pooled specificities were similar, 96%
(94% to 98%) for LF-LAM and 97% (94% to 99%) for Xpert®
MTB/RIF (Figure 8).
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Figure 8. Accuracy of Xpert® MTB/RIF (black circle) and Xpert® MTB/RIF in combination with LF-LAM
(grade 2) (blue circle) plotted in receiver operating characteristic (ROC) space. The dashed lines are only for
illustration to show how sensitivity and specificity changed with the addition of the LF-LAM test.
LF-LAM in combination with sputum Xpert® MTB/RIF
The pooled sensitivity of a combination of LF-LAM and sputum
Xpert® MTB/RIF (either test positive) was 75% (61% to 87%)
representing a 13% (1% to 37%) increase over Xpert® MTB/
RIF alone, while the pooled specificity was 93% (81% to 97%),
representing a 4% (1% to 16%) decrease from Xpert®MTB/RIF
alone (Figure 8).
Uninterpretable index test results
Studies reported few uninterpretable test results. Peter 2012a re-
ported that 1% to 2% of 423 tests remained ’indeterminate’ after
repeat testing. Lawn 2014a reported no invalid or uninterpretable
results. Nakiyingi 2014 reported that a valid LF-LAM result was
obtained on the first attempt for all tests (997/997, 100%). Peter
2015 reported that fewer than 1% of LF-LAM strip tests failed on
the first attempt and required usage of a second strip to produce
valid results.
Investigations of heterogeneity
LF-LAM (grade 2), stratified by CD4 count
We included five studies in the analyses by CD4 count (Andrews
2014; Lawn 2014a; Nakiyingi 2014; Peter 2012a; Peter 2015).
See Figure 9 and Figure 10.
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Figure 9. Forest plots of LF-LAM (grade 2) sensitivity and specificity for TB against a microbiological
reference standard, by CD4 strata (TB Diagnosis). TP = True Positive; FP = False Positive; FN = False Negative;
TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The
figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal
line).
20Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 10. Plots of (A) sensitivity and (B) specificity of LF-LAM (grade 2) for TB diagnosis stratified by CD4
count. Plots were derived using a sample from the posterior distribution of the pooled sensitivity (A) and
specificity (B). Circle represents the pooled estimates (median), with bars representing 95% credible intervals.
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CD4 > 200 cells per µL
The five studies that evaluated participants with CD4 > 200 cells
per µL included 925 HIV-positive participants, 218 (24%) with
TB. Sensitivity estimates ranged from 4% to 100% and specificity
estimates ranged from 83% to 100%. The pooled sensitivity and
specificity (95% CrI) were 15% (8% to 27%) and 96% (89% to
99%).Whenwe limited the analysis to studies involving inpatients
(excluding Peter 2015), the pooled sensitivity and specificity were
14% (6% to 33%) and 97% (88% to 99%).
CD4 ≤ 200 cells per µL
The five studies that evaluated participants with CD4 ≤ 200 cells
per µL included 1344 HIV-positive participants, 605 (45%) with
TB. Sensitivity estimates ranged from 24% to 82% and specificity
estimates ranged from 72% to 98%. The pooled sensitivity and
specificity (95% CrI) were 50% (95% CrI 35% to 67%) and 90%
(95% CrI 78% to 95%). When we limited the analysis to studies
involving inpatients (excluding Peter 2015), the pooled sensitivity
and specificity were 56% (95% CrI 42% to 71%) and 88% (95%
CrI 70% to 95%). The probability that LAM sensitivity and speci-
ficity are higher among participants with CD4 ≤ 200 compared
to those with CD4 > 200 were 100% and 6%, respectively.
CD4 ≤ 100 cells per µL
The five studies that evaluated participants with CD4 ≤ 100 cells
per µL included 859 HIV-positive participants, 402 (47%) with
TB. Sensitivity estimates ranged from 30% to 79% and specificity
estimates ranged from 79% to 98%. The pooled sensitivity and
specificity (95% CrI) were 56% (41% to 70%) and 90% (81% to
95%).Whenwe limited the analysis to studies involving inpatients
(excluding Peter 2015), the pooled sensitivity and specificity were
62% (48% to 75%) and 89% (75% to 95%). The probability
that LAM sensitivity and specificity are higher among participants
with CD4 ≤ 100 compared to those with CD4 > 100 were 99%
and 33%, respectively.
CD4 ≤ 50 cells per µL
The five studies that evaluated participants with CD4 ≤ 50 cells
per µL included 543 HIV-positive participants, 262 (48%) with
TB. Sensitivity estimates ranged from 52% to 73% and specificity
estimates ranged from 67% to 98%. The pooled sensitivity and
specificity (95% CrI) were 62% (49% to 73%) and 89% (77% to
95%).Whenwe limited the analysis to studies involving inpatients
(excluding Peter 2015), the pooled sensitivity and specificity were
63% (49% to 76%) and 86% (71% to 94%). The probability
that LAM sensitivity and specificity are higher among participants
with CD4≤ 50 compared to those with CD4 > 50 were 98% and
25%, respectively.
LF-LAM (grade 2), stratified by clinical setting
Inpatients
In the analysis of LF-LAM (grade 2) for TB diagnosis among
inpatients, we included four studies involving 1299 HIV-positive
inpatients, 517 (40%) with TB (Andrews 2014; Lawn 2014a;
Nakiyingi 2014; Peter 2012a). Sensitivity estimates ranged from
39% to 84% and specificity estimates ranged from 75% to 99%
(Figure 11). The pooled sensitivity and specificity (95% CrI) were
53% (38% to 70%) and 90% (73% to 96%).
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Figure 11. Forest plots of LF-LAM (grade 2) sensitivity and specificity for TB against a microbiological
reference standard, by health care setting (TB Diagnosis). TP = True Positive; FP = False Positive; FN = False
Negative; TN = True Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and
specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI
(black horizontal line).
Outpatients
We identified two studies that evaluated LF-LAM (grade 2) for
TB diagnosis among outpatients (Nakiyingi 2014; Peter 2015).
Sensitivity estimates ranged from 18% to 23% and specificity es-
timates ranged from 93% to 99% (Figure 11).
Sensitivity analyses
LF-LAM (grade 2) for TB diagnosis
In the analysis of LF-LAM (grade 2) for TB diagnosis with re-
spect to a microbiological reference standard, when we limited the
studies to those at low risk of bias for patient selection (exclud-
ing Peter 2015; four studies, 1744 HIV-positive participants, 638
(36%) with TB) pooled sensitivity and specificity were 50% (35%
to 69%) and 91% (75% to 97%). There were insufficient data
to carry out a sensitivity analysis to assess the robustness of meta-
analyses based on the quality of the reference standard.
LF-LAM for TB screening among participants
irrespective of signs and symptoms for TB
Six studies evaluated the accuracy of LF-LAM for screening in
a target population irrespective of TB symptoms (Balcha 2014;
Bjerrum 2015; Drain 2014a; Drain 2014b; LaCourse 2015; Lawn
2012a). Four (67%) studies provided data at grade 1 (1935 par-
ticipants; 333 (17%) with TB) (Balcha 2014; Drain 2014a; Drain
2014b; Lawn 2012a), and three (43%) studies provided data at
grade 2 (1055 participants; 112 (11%) with TB) (Bjerrum 2015;
Drain 2014b; LaCourse 2015). The median CD4 in these stud-
ies ranged from 127 to 437 cells per µL. All studies were carried
out exclusively or largely in an outpatient setting; a single study,
Bjerrum 2015, included a minority of participants from an inpa-
tient setting.
We had limited data for LF-LAM for TB screening as described
below.
LF-LAM (grade 2), microbiological reference standard
Three studies evaluated LF-LAM(grade 2) for TB screening (1055
HIV-positive participants, 112 (11%) with TB), with respect to a
microbiological reference standard (Bjerrum 2015; Drain 2014b;
LaCourse 2015). Sensitivity estimates ranged from 0% to 44%,
and specificity estimates from 94% to 95% (Figure 12). Sensitiv-
ity was lowest in LaCourse 2015. Differences between this study
and others included low TB prevalence (1%), a study population
consisting exclusively of pregnant women, and high median CD4
count.
23Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 12. Forest plots of LF-LAM (grade 1 and 2) sensitivity and specificity for TB against a microbiological
reference standard (TB Screening). TP = True Positive; FP = False Positive; FN = False Negative; TN = True
Negative. Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows
the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
LF-LAM (grade 1), microbiological reference standard
In the analysis of LF-LAM (grade 1) for TB screening with respect
to a microbiological reference standard, we included four studies
(different from those studies contributing data for LF-LAM grade
2) involving 1935 HIV-positive participants, 333 (17%) with TB
(Balcha 2014; Drain 2014a; Drain 2014b; Lawn 2012a). Both
sensitivity and specificity estimates were variable; sensitivity esti-
mates ranged from 26% to 41%, and specificity estimates from
90% to 99% (Figure 12). The pooled sensitivity and specificity
(95% CrI) were 30% (20% to 43%) and 94% (86% to 97%).
LF-LAM (grade 2), composite reference standard
Two studies evaluated LF-LAM for TB screening, with respect to
a composite reference standard (Bjerrum 2015; LaCourse 2015).
Sensitivity estimates ranged from 0% to 36%, and specificity es-
timates ranged from 95% to 98% (Figure 13).
Figure 13. Forest plots of LF-LAM (grade 2) sensitivity and specificity for TB against a composite reference
standard (TB Screening). TP = True Positive; FP = False Positive; FN = False Negative; TN = True Negative.
Between brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the
estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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LF-LAM (grade 2) and existing tests
LF-LAM versus sputum microscopy
Three studies directly compared LF-LAMand sputummicroscopy
in the same participants (Bjerrum 2015; Drain 2014b; LaCourse
2015). The sensitivity of LF-LAM compared to smear in these
studies was 44% (30% to 58%) versus 53% (39% to 66%) for
Bjerrum 2015; 28% (16% to 42%) versus 15% (7% to 27%) for
Drain 2014b; and 0% versus 0%, for LaCourse 2015 (Figure 14).
Figure 14. Accuracy of smear microscopy (black circle) and smear microscopy in combination with LF-LAM
(grade 2) (blue circle) plotted in receiver operating characteristic (ROC) space. The dashed lines are only for
illustration to show how sensitivity and specificity changed with the addition of the LF-LAM test.
LF-LAM in combination with sputum microscopy
Three studies directly compared LF-LAMand sputummicroscopy
in the same participants (Bjerrum 2015; Drain 2014b; LaCourse
2015). The sensitivity of LF-LAM combined with smear in these
studies (compared to smear alone) was 62% (48% to 75%) versus
53% (39% to 66%) for Bjerrum 2015; 35% (23% to 49%) versus
15% (7% to 27%) for Drain 2014b; and 0% versus 0%, for
LaCourse 2015 (Figure 14).
LF-LAM and sputum Xpert® MTB/RIF
We did not have sufficient data to evaluate LF-LAM and spu-
tum Xpert® MTB/RIF (one study, three participants with TB;
LaCourse 2015).
Uninterpretable index test results
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The included studies reported high levels of test interpretability.
Bjerrum 2015 reported that all (100%) 469 LAM tests in their
study yielded interpretable results; similarly, LaCourse 2015 re-
ported no uninterpretable results.
Investigations of heterogeneity
LF-LAM (grade 2), stratified by CD4 count
There were limited data to evaluate LF-LAM (grade 2) by CD4
thresholds.
CD4 > 100 cells per µL
Three studies evaluated LF-LAM in patients with CD4 > 100 cells
per µL (Bjerrum 2015; Drain 2014b; LaCourse 2015). Sensitivity
estimates ranged from 0% to 16% and specificity estimates ranged
from 89% to 95% (Figure 15).
Figure 15. Forest plots of LF-LAM (grade 2) sensitivity and specificity for TB (TB Screening). TP = True
Positive; FP = stratified by CD4 count. False Positive; FN = False Negative; TN = True Negative. Between
brackets are the 95% confidence interval (CI) of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
CD4 ≤ 100 cells per µL
Two studies evaluated LF-LAM in patients with CD4 ≤ 100 cells
per µL (Bjerrum 2015; Drain 2014b). Sensitivity estimates ranged
from 37% to 48% and specificity estimates ranged from 80% to
100% (Figure 15).
Sensitivity analyses, LF-LAM (grade 2) for TB
screening
For TB screening, there were insufficient data to carry out sensi-
tivity analyses to assess the robustness of the meta-analyses based
on methodological quality items.
Other analyses
Concerning inter-reader variability, there was a high degree of
agreement; the included studies reported on inter-reader variabil-
ity in the form of a Kappa statistic or percent concordance between
multiple readers. Four studies of TB diagnosis reported Kappa
statistics ranging from0.78 to 0.97 (Lawn 2014a;Nakiyingi 2014;
Peter 2012a; Peter 2015), and most reported values > 0.92. Two
studies of TB screening reported Kappa values of 0.92 to 0.97
(Bjerrum 2015; Lawn 2012a), and one study reported 100% con-
cordance between readers (Balcha 2014). There were limited data
on intra-reader agreement; Peter 2012a reported a Kappa statistic
of 0.92 to 0.96, which indicated very good agreement.
We acknowledge that patient outcomes are clearly important to
patients, decisionmakers, and thewiderTBcommunity.However,
we could not systematically address outcomes in addition to diag-
nostic accuracy as they would have required a different method-
ology. Nonetheless, we looked for and summarized the data on
patient outcomes from the included studies, including data from
secondary analyses. Six included studies provided data on the as-
sociation of LF-LAM and mortality in publications and related re-
ports or in unpublished data (Balcha 2014; Bjerrum 2015; Drain
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2014c; Lawn 2012a; Nakiyingi 2014; Peter 2015; see Table 2).
These studies were conducted in both inpatient and outpatient
settings. Data on patient outcomes were largely restricted to post-
hoc analyses. Nonetheless, available data consistently suggested
higher disease severity among LF-LAM positive TB participants
than LF-LAM negative TB participants. All six studies showed a
consistent finding of increasingmortality with LF-LAMpositivity,
despite considerable variability in the length of follow-up, method
of TB diagnosis, and provision of treatment. We noted that the
investigators in these studies did not use the results of LF-LAM to
decide TB treatment initiation.
Balcha 2014 reported highermortality (20%versus 3%, P<0.001)
in LF-LAM positive than LF-LAM negative participants. Simi-
larly Manabe 2014 reported higher mortality (28% versus 13%,
P = 0.035) in LF-LAM positive than LF-LAM negative TB par-
ticipants (secondary analysis, Nakiyingi 2014). Manabe 2014 ad-
ditionally found higher mortality in LF-LAM positive partici-
pants without microbiological evidence of TB (34% versus 19%
for LF-LAM positive and LF-LAM negative participants, respec-
tively). Lawn 2012c found that among 23 TB participants who
were LF-LAM positive, five people died (22%) compared to zero
deaths (0/36) among TB participants who were LF-LAM negative
(secondary analysis, Lawn 2012a). In another secondary analysis
(Lawn 2012a), Lawn 2013b reported that LF-LAM sensitivity was
100% among TB participants who died compared to 25% among
TB participants who were alive at 90 days (P = 0.002). Peter 2015
reported mortality of 25% and 11% in LF-LAM positive and LF-
LAM negative participants, respectively. Finally, Bjerrum 2015 re-
ported that among all participants, 49% of those who were LF-
LAM-positive died versus 14% of those who were LF-LAM neg-
ative (P < 0.001). Among TB participants, 54% of LF-LAM-pos-
itive participants died compared to only 16% of those who were
LF-LAM negative (P = 0.003).
Bjerrum 2015 and Drain 2015 (related report, Drain 2014c) in-
cluded treatment data in their studies. Bjerrum 2015 reported that
among TB participants who received TB treatment, 31% of those
who were LF-LAM positive died compared to only 4% of those
who were LF-LAM negative. Among TB participants who did not
receive treatment at the time of assessment in the study, 100% of
those who were LF-LAM positive died compared to 33% of those
who were LF-LAM negative. In each of these studies, LF-LAM
results were unavailable to clinicians. In another post-hoc analysis,
Peter 2013 reported that among inpatients, LF-LAM-positive TB
participants missed by empirical early treatment had lower CD4
counts and higher median illness severity scores, compared to par-
ticipants who received early treatment based on clinical decision
making. Drain 2015 reported LF-LAM responses over time. They
reported that among participants receiving TB therapy, having a
positive LF-LAMtest at the two-month visit was associatedwith an
adjusted hazard ratio (HR) of 5.58 for mortality (median follow-
up time of 49 months) compared to participants with a negative
LF-LAM test at the two-month visit. Participants with a positive
LF-LAM at six months had an adjusted HR of 42.1 for mortality
during study follow-up. They found no difference (adjusted HR
1.41, P = 0.49) in mortality comparing baseline LF-LAM results.
Concerning the impact of LF-LAM implementation on patient
outcomes, Peter 2016 found that, in HIV-positive inpatients, LF-
LAM in combination with routine diagnostic tests to guide the
rapid initiation of TB treatment was associated with a relative risk
reduction of 17% (95% CI 4% to 28%) in eight-week mortality
compared with routine diagnostic tests alone (no LF-LAM). We
are also aware of two additional studies with data on the impact of
LF-LAM on patient outcomes expected in 2016 (Grant ongoing;
NCT01990274).
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Summary of findings
Review question: what is the diagnost ic accuracy of LF-LAM (grade 2) for diagnosing tuberculosis (TB) in adults living with HIV?
Participants/population: HIV-posit ive adults with symptoms of TB
Index test: LF-LAM (grade 2)
Role: a replacement test or addit ional test along with sputum smear microscopy or sputum Xpert® MTB/ RIF
Reference standard: microbiological (mainly mycobacterial culture)
Studies: cross-sect ional
Setting: inpat ient and outpat ient
Limitations: the main lim itat ions of the review were the use of a lower quality reference standard in most included studies, and the small number of studies and part icipants
included in the analyses
Pooled sensitivity: 0.45 (95% CrI: 0.29 to 0.63); pooled specif icity: 0.92 (95% CrI: 0.80 to 0.97)
Test result Number of results per 1000 participants tested
(95% CrI)
Number of participants (studies) Quality of the evidence (GRADE)
Prevalence 10% Prevalence 30%
True positives
(pat ients correct ly classif ied as
having TB)





(pat ients incorrect ly classif ied as
not having TB)
55 (37 to 71) 165 (111 to 213)
True negatives
(pat ients correct ly classif ied as
not having TB)





(pat ients incorrect ly classif ied as
having TB)
72 (27 to 180) 56 (21 to 140)
Inconclusive Inf requent



































































































































































Abbreviations: Crl: credible interval; LF-LAM: lateral f low urine lipoarabinomannan assay; GRADE: Grading of Recommendations Assessment, Development and Evaluat ion;
HIV: human immunodef iciency virus; TB: tuberculosis
GRADE quality of evidence (GRADEpro 2015; Schünemann 2013)
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
The table displays normalised f requencies within a hypothet ical cohort of 1000 pat ients at two dif ferent TB prevalences (pre-test probabilit ies): 10% and 30%. Credible lim its
were est imated based on those around the point est imates for pooled sensit ivity and specif icity
Note: the results on this table should not be interpreted in isolat ion f rom the results of the individual included studies contribut ing to each summary test accuracy measure.
These are reported in the main body of the text of the review
1We used QUADAS-2 to assess risk of bias. We considered one study to be at high risk of bias because this study excluded
pat ients who were unable to produce sputum (Peter 2015). We did not downgrade the evidence.
2Four included studies were performed in inpat ient sett ings (Andrews 2014; Lawn 2014a; Nakiyingi 2014; Peter 2012a).
3The wide 95% CrI for true posit ives and false negat ives may lead to dif ferent decisions depending on which credible lim its
are assumed. We downgraded the evidence by one level. Of note, in a subgroup analysis of pat ients with CD4 count ≤ 100
cells per µL, the pooled sensit ivity increased to 56% (95% CrI 41% to 70%) while the pooled specif icity decreased slight ly to
90% (95% CrI 81% to 95%; f ive studies, 859 part icipants, 402 with conf irmed TB).
4We used QUADAS-2 to assess risk of bias. We considered three studies to be at high risk of bias because they used a lower
quality reference standard (Andrews 2014; Peter 2012a; Peter 2015). We downgraded the evidence by one level.
5The wide 95% CrI for true negat ives and false posit ives may lead to dif ferent decisions depending on which credible lim its



































































































































































Review question: what is the accuracy of LF-LAM (grade 2) for screening for tuberculosis (TB) in adults living with HIV?
Patients/population: HIV-posit ive adults regardless of signs and symptoms of TB
Index test: LF-LAM (grade 2)
Role: a replacement test or addit ional test along with sputum smear microscopy or sputum Xpert® MTB/ RIF
Reference standard: microbiological (mainly mycobacterial culture)
Studies: cross-sect ional
Setting: outpat ient
Limitations: the main lim itat ions of the review were the use of a lower quality reference standard in all included studies, and the small number of studies and part icipants
included in the analyses
Sensitivity range: 0% to 44%; specif icity range: 94% to 95%
Test result Number of results per 1000 participants tested Number of participants (studies) Quality of the evidence (GRADE)
Prevalence 1% Prevalence 10%
True positives
(pat ients correct ly classif ied as
having TB)





(pat ients incorrect ly classif ied as
not having TB)
6 to 10 56 to 99
True negatives
(pat ients correct ly classif ied as
not having TB)





(pat ients incorrect ly classif ied as
having TB)
49 to 59 45 to 54
Inconclusive Inf requent



































































































































































Abbreviations: LF-LAM: lateral f low urine lipoarabinomannan assay; HIV: human immunodef iciency virus; GRADE: Grading of Recommendations Assessment, Development
and Evaluat ion; TB: tuberculosis
GRADE quality of evidence (GRADEpro 2015; Schünemann 2013)
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
The table displays normalised f requencies within a hypothet ical cohort of 1000 pat ients at two dif ferent TB prevalences (pre-test probabilit ies): 1% and 10%. Credible lim its
were est imated based on those around the point est imates for pooled sensit ivity and specif icity
Note: the results on this table should not be interpreted in isolat ion f rom the results of the individual included studies contribut ing to each summary test accuracy measure.
These are reported in the main body of the text of the review
LF-LAM for TB screening was of ten performed at grade 1, which is no longer recommended. Nonetheless, we found pooled
sensit ivity and pooled specif icity of 30%(95%CrI 20%to 43%) and 94%(95%CrI 86%to 97%), four studies, 1935 part icipants,
333 (17%) TB.
1We used QUADAS-2 to assess risk of bias. We considered one study to be at high risk of bias because the study excluded
pat ients who were unable to produce sputum. All studies used a lower quality reference standard. We downgraded the
evidence by two levels.



































































































































































D I S C U S S I O N
This systematic review summarizes the current literature and in-
cludes 12 unique studies on the accuracy of lateral flow urine
lipoarabinomannan assay (LF-LAM) for tuberculosis (TB) in peo-
ple with human immunodeficiency virus (HIV). Six studies used
LF-LAM for TB diagnosis in participants with signs and symp-
toms of TB. The studies of TB diagnosis were largely conducted
in inpatient settings and had high TB prevalence. Six studies used
LF-LAM for systematic screening of participants for TB regardless
of their symptoms. The studies of TB screening were conducted
exclusively or predominantly in outpatient settings and, compared
to studies of TB diagnosis, had lower TB prevalence and involved
patients with higher CD4 counts. All studies were conducted in
low- and middle-income countries.
LF-LAM for TB diagnosis
See ’Summary of findings’ table 1 (Summary of findings 1).
For TB diagnosis, the pooled sensitivity of LF-LAM (grade 2)
was low (45%) with relatively high pooled specificity (92%). We
explored an alternative threshold (grade 1) for test positivity and
found that both sensitivity (59%) and specificity (78%) were low.
We found higher sensitivity (59%) when LF-LAM was combined
with microscopy (either test positive) which represented an in-
crease of 19% over sputum microscopy alone, although pooled
specificity decreased 6% from microscopy alone (four studies). In
planned investigations, we observed an inverse correlation between
LF-LAM sensitivity and CD4 count, with increasing sensitivity as
patientCD4count decreased (increased from15% inpatientswith
CD4 cell count > 200 cells per µL to 62% in patients with CD4
≤ 50 cells per µL) This inverse correlation may reflect increased
LF-LAM sensitivity among those with advanced disease, dissem-
inated disease, or higher bacillary burden. Pooled specificity was
similar across CD4 strata. These findings suggest that LF-LAM
may aid in the diagnosis of TB in seriously ill patients with low
CD4 counts. While the test does not identify all TB cases, it may
be of particular value in diagnosing seriously ill patients who are
unable to produce sputum or cannot be diagnosed with other TB
diagnostic tests. We a priori planned to investigate and expected
to find higher accuracy in patients with lower CD4 counts and
patients who were hospitalized. In subgroup analyses, we found
LF-LAM (grade 2) sensitivity was generally higher among inpa-
tients (53%) than among outpatients (18% to 23%). Although
subgroup comparisons in diagnostic accuracy reviews are obser-
vational and suffer from the same limitations as all observational
findings (for example, confounding between characteristics), there
is a scientific rationale for this finding in that inpatients are likely
to have higher disease severity or higher bacillary burden.
LF-LAM for screening for TB
See ’Summary of findings’ table 2 (Summary of findings 2).
Few studies evaluated LF-LAM for TB screening among individu-
als irrespective of symptoms at the currently recommended grade 2
threshold for positivity. Sensitivity ranged from 0% to 44%, while
specificity ranged from 94% to 95%. We explored an alternative
threshold (grade 1) for positivity and found low pooled sensitivity
(30%) and reasonably high pooled specificity (94%).
Summary of main results
Wehave summarized themain results in the ’Summary of findings’
tables (Summary of findings 1; Summary of findings 2).
• For TB diagnosis in HIV-positive people with signs and
symptoms suggestive of TB, the pooled sensitivity and specificity
(95% credible interval (CrI)) of LF-LAM (grade 2) were 45%
(29% to 63%) and 92% (80% to 97%).
• For TB screening in HIV-positive people regardless of signs
and symptoms of TB, LF-LAM (grade 2) sensitivity estimates
ranged from 0% to 44% and specificity estimates from 94% to
95%.
• Few studies used a higher quality reference standard with
more than one type of clinical specimen.
We note that the band intensity corresponding to grade 2 in this
review corresponds to the current manufacturer threshold for pos-
itivity (that is, grade 1 on the new manufacturer reference card).
Application of the meta-analysis to a hypothetical
cohort
LF-LAM for TB diagnosis
See ’Summary of findings’ table 1 (Summary of findings 1).
If the pooled sensitivity and specificity estimates for LF-LAM
(grade 2) are applied to a hypothetical cohort of 1000 HIV-posi-
tive individuals where 300 (30%) of those with symptoms actually
have TB, LF-LAM would correctly identify 135 people as having
TB while missing 165 people with TB. In this same population
of 1000 people, where 700 do not have TB, the test will correctly
classify 644 people as not having TB while misclassifying 56 as
having TB.
LF-LAM for TB screening
See ’Summary of findings’ table 2 (Summary of findings 2).
If the ranges in sensitivity and specificity for LF-LAM (grade 2) are
applied to a hypothetical cohort of 1000 HIV-positive individuals
where 10 (1%) of those being screened for TB actually have TB,
LF-LAMwould correctly identify zero to four people as having TB
while missing six to 10 people with TB. In this same population
of 1000 people, where 990 do not have TB, the test will correctly
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classify 931 to 941 people as not having TB while misclassifying
49 to 59 as having TB.
Strengths and weaknesses of the review
The findings in this review are based on comprehensive search-
ing, strict inclusion criteria, and standardized data extraction. The
strength of our review is that it enabled an assessment of the accu-
racy of LF-LAM in HIV-positive people for two purposes, diag-
nosis and screening. We determined test accuracy at two different
positivity cut-offs and for LF-LAM combined with existing spu-
tum-based tests. We also investigated heterogeneity with respect
to the CD4 count. The main limitations of the review were the
use of a lower quality reference standard in most included studies,
and the small number of studies and participants included in the
analyses. The results should, therefore, be interpreted with cau-
tion.
Completeness of evidence
This data set involved comprehensive searching and correspon-
dence with experts in the field and the testmanufacturer to identify
additional studies, as well as repeated correspondence with study
authors to obtain additional and unpublished data. The search
strategy included studies published in all languages. However, as
diagnostic accuracy studies are poorly indexed, we acknowledge
that we may have missed some studies despite the comprehensive
search.
Accuracy of the reference standards used
In a diagnostic test accuracy systematic review, the reference stan-
dard is the best available test to determine the presence or ab-
sence of the target condition. A microbiological reference stan-
dard, primarily culture, is considered the best reference standard
for TB. HIV-positive TB patients may have pulmonary TB, extra-
pulmonary TB, or both pulmonary and extrapulmonary TB. Due
to the difficulties in diagnosing HIV-associated TB, it is recom-
mended that multiple cultures from sputum and other specimen
types be evaluated. We therefore considered a reference standard
using two or more specimen types to be of higher quality than a
reference standard using one specimen type. The higher quality
reference standard is better at classifying which patients have and
do not have TB. A lower quality reference standard maymiss some
TB cases and classify some TB patients as not having TB. This
may make a truly positive LF-LAM result seem like an FP leading
to an underestimation of specificity. However, in the review, only
two studies (33%) for TB diagnosis and one study (17%) for TB
screening used a higher quality reference standard.
Compared with a microbiological reference standard, a composite
reference standard using clinical informationmay also be less likely
to misclassify TB patients as not having TB, especially in patients
with paucibacillary pulmonary disease in whom sputum culture
may be negative. We found LF-LAM specificity ranged from 96%
to 99% for TB diagnosis with respect to a composite reference
standard. However, we had limited data and these findings should
be interpreted with caution.
Quality and quality of reporting of the included
studies
There were few studies that included extrapulmonary specimens
in addition to sputum, and few studies that included participants
unable to expectorate sputum. We had limited data to address
these quality items in sensitivity analyses and acknowledge that
these features may have contributed to risk of bias in the accuracy
estimates. For TB diagnosis, in the patient selection domain, we
considered two studies (33%) to be at high risk of bias, and in the
reference standard domain, we considered four studies (66%) to
be at high risk of bias. For TB screening, in the patient selection
domain, we considered two studies (33%) to be at high risk of bias
and in the reference standard domain, we considered five studies
(83%) to be at high risk of bias. Using the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
approach, we judged the evidence for diagnostic accuracy of LF-
LAM to be of low or very low quality. This means that our confi-
dence in the effect estimate is limited and the true effect may be
substantially different from the estimate of the effect. In general,
studies were fairly well reported, though we corresponded with
almost all study authors for additional data and missing informa-
tion.
Applicability of findings to the review question
We had low concern about the applicability of the included stud-
ies to our review question as assessed by the Quality Assessment
of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. We consid-
ered the degree to which setting, patient spectrum, index test, and
reference standard characteristics could affect test accuracy esti-
mates. Although all studies were performed in low- or middle-in-
come countries, we think, given the underlying pathophysiology
of HIV-associated TB, LF-LAMwould perform similarly in high-
income countries. This review evaluated LF-LAM at the current
manufacturer-recommended cut-off for positivity, as well as an
alternative threshold. Therefore the findings in this review should
be considered applicable to the test. However, it is important to
note that this review assessed sensitivity and specificity in applied
research settings. Although the participant characteristics and set-
tings matched our review question in most cases, as studies were
carried out under research conditions, it is possible that the accu-
racy of LF-LAM may be lower in routine practice settings.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Among HIV-positive people who present with symptoms sugges-
tive of TB, this Cochrane review found low LF-LAM sensitiv-
ity, which suggests that LF-LAM cannot be relied on alone for
the diagnosis of TB. For TB diagnosis, the combination of LF-
LAM with sputum microscopy suggests increased sensitivity for
TB compared to either test alone, but with a decrease in speci-
ficity. The findings also suggest increased sensitivity at lower CD4
counts compared to higher CD4 counts. However, we had lim-
ited data and these findings should be interpreted with caution.
Nonetheless, in HIV-positive people with low CD4 counts who
are seriously ill, LF-LAM may help with the diagnosis of TB. As a
simple point-of-care test that does not depend upon sputum eval-
uation, there may also be situations where LF-LAM testing offers
advantages compared to existing sputum-based tests.
Clinicians must consider the need for additional testing when in-
terpreting negative LF-LAM results. The consequences of false
negative results are increased risk of morbidity and mortality, de-
layed treatment initiation, and the continued risk of TB transmis-
sion. The consequences of false positive results are likelihood of
anxiety and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; possible stigma associated
with a diagnosis of TB; and the chance that a false positive may
halt further diagnostic evaluation. As LF-LAM does not offer in-
formation about drug-resistance, some patients with unidentified
drug-resistant TB may be inappropriately treated with a regimen
appropriate only for drug-sensitive disease.
For TB screening among HIV-positive people regardless of TB
symptoms, LF-LAM yielded low sensitivity and relatively high
specificity. These findings do not support the use of LF-LAM as
screening test for TB.
A systematic review of economic evaluations of LF-LAM for TB,
Dowdy 2015 [pers comm], identified two studies that evaluated
the addition of LF-LAM to existing diagnostic strategies including
smear, Xpert®MTB/RIF, and clinical diagnosis (Shah 2013; Sun
2013). Both studies evaluated LF-LAM in the African setting; one
study was restricted to inpatients with CD4 < 100 cells per µL
(Sun 2013). The two studies, using similar methodologies, found
that incorporation of LF-LAM into TB diagnostic algorithms for
HIV-positive people is highly cost-effective. This result was robust
to wide sensitivity analyses that explored uncertainties in input
parameter estimates. Given the low cost of LF-LAM, the findings
suggest that the cost-effectiveness of LF-LAMultimately converges
to the cost-effectiveness of HIV and TB treatment because the
incremental diagnostic costs for LF-LAMare dwarfed by treatment
costs for those who test positive. Key parameters that influenced
the degree of LF-LAM cost-effectiveness included the specificity
of LF-LAM, prevalence of TB in the target population, the life
expectancy of HIV-infected TB survivors, and costs of treating
TB and HIV.
Implications for research
Future studies that evaluate the diagnostic accuracy of non-spu-
tum-based tests for TB, such as LF-LAM, in HIV-positive people
should use a reference standard that includes at least two speci-
men types or extrapulmonary specimens in addition to sputum.
Moreover, future studies should include patients unable to expec-
torate sputum in the analysis. These features of study design may
decrease the risk of bias in the accuracy estimates. Further research
on effective implementation of LF-LAM within routine clinical
practice is needed because the test can only influence clinical prac-
tice if the results are believed and acted upon.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andrews 2014
Study characteristics
Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: Signs and symptoms of sepsis
Age: median 36 (interquartile range (IQR) 29 to 45)
Sex, female: 39%
HIV infection: 100%




TB incidence rate: 410 per 100,000
Number (proportion) of TB cases in the study: 19 (20%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: mycobacteraemia; reference standard: mycobacterial blood culture (BacTec)
Flow and timing The study authors obtained all specimens at the same time during study enrolment
Comparative
Notes The study authors performed mycobacterial blood cultures on all participants and did not exclude
participants based on lack of sputum
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Andrews 2014 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: Irrespective of symptoms, patients with CD4 < 350 or WHO stage
4 who could produce sputum
Age: median 33.5 (IQR 26.5 to 40)
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TB incidence rate: 224 per 100,000
Number (proportion) of TB cases in the study: 128 (17%)
Index tests LF-LAM
Target condition and reference
standard(s)
HIV-associated TB; expectorated sputum mycobacterial culture (liquid) and some lymph node
mycobacterial culture (liquid)
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors excluded individuals who were unable to expectorate
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Balcha 2014 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: irrespective of symptoms, patients who could produce sputum
Age: mean 39 (standard deviation (SD) 10)
Sex, female: 64%
HIV infection: 100%




TB incidence rate: 66 per 100,000
Number (proportion) of TB cases in the study: 55 (12%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target: pulmonary TB; reference standard: sputum mycobacterial culture (solid and liquid); no
extrapulmonary specimens tested
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Bjerrum 2015 (Continued)
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors excluded individuals without some respiratory specimen available and did not
attempt to identify extrapulmonary TB. When using a composite reference standard, the study au-
thors considered 5 LAM-positive and 11 LAM-negative (grade 2) patients ’unclassifiable’ regarding
their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: not specified
Age: mean 35.6 (SD 9.8)
Sex, female: 45%
HIV infection: 100%




TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 60 (18%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: pulmonary TB; reference standard: mycobacterial (solid and liquid) culture of
sputum without evaluation of extrapulmonary TB
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors performed sputum induction for individuals who could not expectorate. They
excluded individuals without some respiratory specimen available and did not attempt to identify
extrapulmonary TB.When using a composite reference standard, the study authors did not consider
any patients ’unclassifiable’ regarding their TB status
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Drain 2014a (Continued)
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: not specified
Age: not specified
Sex, female: not specified
HIV infection: 100%




TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 54 (17%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: pulmonary TB; reference standard: mycobacterial (solid and liquid) culture of
sputum without testing of extrapulmonary TB
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors performed sputum induction for individuals who could not expectorate. They
excluded individuals without some respiratory specimen available and did not attempt to identify
extrapulmonaryTB.Whenusing a composite reference standard,The study authors did not consider
any patients ’unclassifiable’ regarding their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Drain 2014b (Continued)
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Cross-sectional, patient selection by convenience
Patient characteristics and set-
ting
Presenting signs and symptoms: signs and symptoms suggestive of TB, but not specified
Age: not specified
Sex, female: not specified
HIV infection: 100%
History of TB: not stated
Sample size: 90
Clinical setting: primary care clinic and tertiary hospital
Country: South Africa
TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 57 (63%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: pulmonary TB; reference standard: mycobacterial (solid and liquid) culture of
sputum without testing of extrapulmonary samples
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors performed sputum induction for individuals who could not expectorate. They
excluded individuals without some respiratory specimen available and did not attempt to iden-
tify extrapulmonary TB. All included individuals were smear-negative. When using a composite
reference standard, the study authors did not consider any patients ’unclassifiable’ regarding their
TB status. Using a composite reference standard, the study authors categorized all participants was
having TB
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Drain 2014c (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: irrespective of symptoms
Other characteristics: pregnant women
Age: median 25 (IQR 22 to 30)
Sex, female: 100%
HIV infection: 100%
52Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
LaCourse 2015 (Continued)




TB incidence rate: 268 per 100,000
Number (proportion) of TB cases in the study: 3 (1%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: pulmonary TB; reference standard: expectorated sputum mycobacterial culture
(liquid)
Flow and timing All patients were included in the analysis
Comparative
Notes This study included 14 patients without sputum. The study authors did not perform sputum in-
duction or test extrapulmonary specimens. When using a composite reference standard, the study
authors considered 0 LAM-positive and 17 LAM-negative (grade 2) patients ’unclassifiable’ regard-
ing their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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LaCourse 2015 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: irrespective of symptoms, patients referred for antiretroviral therapy
Age: median 34.1 (IQR 28.6 to 41.3)
Sex, female: 64%
HIV infection: 100%




TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 91 (18%)
Index tests LF-LAM
Target condition and reference
standard(s)
Target condition: HIV-associated TB; expectorated sputum mycobacterial (liquid) culture
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Lawn 2012a (Continued)
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors performed sputum induction for all individuals. They excluded individuals
without some respiratory specimen available and did not attempt to identify extrapulmonary TB.
When using a composite reference standard, the study authors considered 6 LAM-positive and 418
LAM-negative (grade 1) patients ’unclassifiable’ regarding their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: not specified
Age: Median 36.4 (IQR 29.0 to 42.4)
Sex, female: 61%
HIV infection: 100%




TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 136 (33%)
Index tests LF-LAM
Target condition and reference
standard(s)
HIV-associated TB; sputum mycobacterial culture (liquid), sputum Xpert® MTB/RIF, mycobac-
terial blood culture, 2 urine Xpert® MTB/RIF, and additional extrapulmonary culture and nucleic
acid amplification test (NAAT)
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors performed sputum induction for all individuals and included those without
sputum. They also performedmultiple tests on extrapulmonary specimens.When using a composite
reference standard, the study authors considered 3 LAM-positive and 270 LAM-negative (grade 2)
patients ’unclassifiable’ regarding their TB status
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Lawn 2014a (Continued)
Did all patients receive the same
reference standard?
Yes






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: signs and symptoms suggestive of TB, but not specified
Age: median 33 (IQR 29 to 37)
Sex, female: 63%
HIV infection: 100%
History of TB: not stated
Sample size: 997
Clinical setting: inpatient and outpatient
Country: South Africa and Uganda
TB incidence rate: 860 per 100,000 (South Africa); 166 per 100,000 (Uganda)
Number (proportion) of TB cases in the study: 367 (37%)
Index tests LF-LAM
Target condition and reference
standard(s)
HIV-associated TB; sputum mycobacterial culture (liquid and solid), mycobacterial blood cultures;
sputum induction for those unable to expectorate
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors excluded patients who were unable to expectorate and those without a specimen
following induction. When using a composite reference standard, the study authors did not consider
any patients ’unclassifiable’ regarding their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Nakiyingi 2014 (Continued)
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: signs and symptoms suggestive of TB, but not specified
Age: median 35 (IQR 29 to 40)
Sex, female: 63%
HIV infection: 100%




TB incidence rate: 860 per 100,000
Number (proportion) of TB cases in the study: 116 (48%)
Index tests LF-LAM
Target condition and reference
standard(s)
There was no protocol to ensure a minimum standard of testing
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors included all patients with symptoms of TB irrespective of their ability to produce
sputum; clinicians chose the reference standard rather than it being directed by the study protocol.
The reference standard included testing of pulmonary and extrapulmonary sites by mycobacterial
culture. When using a composite reference standard, the study authors considered 12 LAM positive
and 54 LAM-negative (grade 2) patients ’unclassifiable’ regarding their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Peter 2012a (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No






Patient sampling Cross-sectional, consecutive enrolment
Patient characteristics and set-
ting
Presenting signs and symptoms: signs and symptoms suggestive of TB, but not specified
Age: median 36 (IQR 30 to 41)
Sex, female: 46%
HIV infection: 100%
History of TB: not stated
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Country: South Africa, Tanzania, Zambia
TB incidence rate: 860 per 100,000 (South Africa); 164 per 100,000 (Tanzania); 410 per 100,000
(Zambia)
Number (proportion) of TB cases in the study: 181 (32%)
Index tests LF-LAM
Target condition and reference
standard(s)
HIV-associated TB; sputum mycobacterial (liquid) culture
Flow and timing All patients were included in the analysis
Comparative
Notes The study authors excluded individuals unable to expectorate and did not test extrapulmonary
specimens. When using a composite reference standard, the study authors considered 42 LAM-
positive and 162 LAM-negative patients as ’unclassifiable’ regarding their TB status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
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Peter 2015 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes




Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Achkar 2011 Review/editorial/commentary
Agha 2013 Index test not studied
Amoudy 1997 Index test not studied
Boehme 2005 Index test not studied
Boyles 2012 Index test not studied
Chan 2000 Index test not studied
Cho 1997 Index test not studied
Conesa-Botella 2007 Index test not studied
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(Continued)
Daley 2009 Index test not studied
Deng 2011 Index test not studied
Dheda 2009 Index test not studied
Dheda 2010 Index test not studied
Elsawy 2012 Index test not studied
Gounder 2011 Index test not studied
Hamasur 2001 Index test not studied
Hanrahan 2012 Review/editorial/comment
Kashino 2008 Index test not studied
Kerkhoff 2014a Duplicate data
Kerkhoff 2014b Duplicate data
Koulchin 2007 Index test not studied
Kroidi 2014 Index test not studied
Lawn 2009 Index test not studied
Lawn 2012b Review/editorial/comment
Lawn 2012c Insufficient data
Lawn 2012d Review/editorial/comment
Lawn 2013b Insufficient data
Lawn 2014b Review/editorial/comment
Manabe 2014 Duplicate data
Mukundan 2012 Index test not studied
Mutetwa 2009 Index test not studied
Patel 2009 Index test not studied
Patel 2010 Index test not studied
Peter 2011 Duplicate data
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(Continued)
Peter 2012b Duplicate data
Peter 2012c Duplicate data
Peter 2013 Duplicate data
Reid 2015 Insufficient data
Reither 2009 Index test not studied
Sada 1992 Index test not studied
Savolainen 2013 Index test not studied
Schmidt 2011 Index test not studied
Shah 2009 Index test not studied
Shah 2010 Index test not studied
Shah 2013 Duplicate data
Shah 2014 Duplicate data
Singh 2011 Index test not studied
Sun 2013 Insufficient data
Swaminathan 2012 Review/editorial/comment
Talbot 2012 Review/editorial/comment
Tessema 2001 Index test not studied
Tessema 2002a Index test not studied
Tessema 2002b Index test not studied
Tlali 2014 Insufficient data
Van Rie 2013 Insufficient data
Wood 2012 Index test not studied
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Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Target condition: active TB; reference standard: MGIT liquid TB culture
Flow and timing
Comparative
Notes A standard diagnostics package consisting of smear microscopy and culture will be compared with
a novel diagnostics package involving point-of-care sputum GeneXpert MTB/RIF performed at a
mobile or conventional clinic, sputum culture, and lateral flow urinary lipoarabinomannan (LAM)
testing
Characteristics of ongoing studies [ordered by study ID]
Grant ongoing
Trial name or title XPHACTOR
Target condition and reference standard(s) Target condition: TB (both pulmonary and extrapulmonary); reference standard: liquid
culture
Index and comparator tests Index test: Determine TB-LAM; Comparator tests: Xpert® MTB/RIF
Starting date Unknown
Contact information Allison Grant, Aurum Institute
Notes
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 Diagnosis of TB against
microbiological reference at
Grade 1: all participants
6 2402
2 Diagnosis of TB against
microbiological reference at
Grade 2: all participants
5 2313
3 Diagnosis of TB against
composite reference at Grade
1: all participants
3 1585
4 Diagnosis of TB against
composite reference at Grade
2: all participants
3 1586
5 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 > 200
4 870
6 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 < 200
4 1131
7 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 > 100
4 1289
8 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 < 100
4 712
9 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 > 50
4 1534
10 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 < 50
4 467
11 Diagnosis of TB against
microbiological reference at
Grade 2, CD4 > 200
5 925
12 Diagnosis of TB against
microbiological reference at
Grade 2, CD4 < 200
5 1344
13 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 > 100
5 1410
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14 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 < 100
5 859
15 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 > 50
5 1726
16 Diagnosis of TB against
microbiological reference at
Grade 1, CD4 < 50
5 543
















21 Diagnosis of TB with LAM
at Grade 2 (among studies
comparing with smear)
4 1875
22 Diagnosis of TB with smear
(among studies comparing with
LAM)
4 1875
23 Diagnosis of TB with
combination of LAM at Grade
2 with smear
4 1876
24 Diagnosis of TB with LAM
at Grade 2 (among studies
comparing with Xpert®)
3 909
25 Diagnosis of TB with Xpert®
(among studies comparing with
LAM)
3 909
26 Diagnosis of TB with
combination of LAM at Grade
2 with Xpert®
3 909
27 Screening for TB against
microbiological reference at
Grade 1: all participants
4 1935
28 Screening for TB against
microbiological reference at
Grade 2: all participants
3 1055
29 Screening for TB against
composite reference at Grade
1: all participants
2 662
30 Screening for TB against
composite reference at Grade
2: all participants
2 735
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31 Screening for TB against
microbiological reference at
Grade 1, CD4 > 200
2 594
32 Screening for TB against
microbiological reference at
Grade 1, CD4 < 200
2 678
33 Screening for TB against
microbiological reference at
Grade 1, CD4 > 100
3 1221
34 Screening for TB against
microbiological reference at
Grade 1, CD4 < 100
3 579
35 Screening for TB against
microbiological reference at
Grade 1, CD4 > 50
2 1152
36 Screening for TB against
microbiological reference at
Grade 1, CD4 < 50
2 120
37 Screening for TB against
microbiological reference at
Grade 2, CD4 > 100
3 694
38 Screening for TB against
microbiological reference at
Grade 2, CD4 < 100
2 262




40 Screening for TB with
LAM at Grade 2 (among
studies comparing with smear
microscopy)
3 1057




42 Screening for TB with the
combination of LAM (Grade
2) and smear microscopy
3 1075
69Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 1. Diagnosis of TB against microbiological reference at Grade 1: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 1 Diagnosis of TB against microbiological reference at Grade 1: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 19 37 0 37 1.00 [ 0.82, 1.00 ] 0.50 [ 0.38, 0.62 ]
Drain 2014c 24 5 33 28 0.42 [ 0.29, 0.56 ] 0.85 [ 0.68, 0.95 ]
Lawn 2014a 64 13 72 264 0.47 [ 0.38, 0.56 ] 0.95 [ 0.92, 0.97 ]
Nakiyingi 2014 226 141 141 488 0.62 [ 0.56, 0.67 ] 0.78 [ 0.74, 0.81 ]
Peter 2012a 77 43 39 82 0.66 [ 0.57, 0.75 ] 0.66 [ 0.57, 0.74 ]
Peter 2015 68 81 113 307 0.38 [ 0.30, 0.45 ] 0.79 [ 0.75, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Diagnosis of TB against microbiological reference at Grade 2: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 2 Diagnosis of TB against microbiological reference at Grade 2: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 16 14 3 60 0.84 [ 0.60, 0.97 ] 0.81 [ 0.70, 0.89 ]
Lawn 2014a 53 3 83 274 0.39 [ 0.31, 0.48 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 136 21 231 609 0.37 [ 0.32, 0.42 ] 0.97 [ 0.95, 0.98 ]
Peter 2012a 58 31 58 94 0.50 [ 0.41, 0.59 ] 0.75 [ 0.67, 0.82 ]
Peter 2015 41 27 140 361 0.23 [ 0.17, 0.29 ] 0.93 [ 0.90, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Diagnosis of TB against composite reference at Grade 1: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 3 Diagnosis of TB against composite reference at Grade 1: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nakiyingi 2014 243 124 181 448 0.57 [ 0.52, 0.62 ] 0.78 [ 0.75, 0.82 ]
Peter 2012a 112 1 75 26 0.60 [ 0.52, 0.67 ] 0.96 [ 0.81, 1.00 ]
Peter 2015 43 38 145 149 0.23 [ 0.17, 0.30 ] 0.80 [ 0.73, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Diagnosis of TB against composite reference at Grade 2: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 4 Diagnosis of TB against composite reference at Grade 2: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nakiyingi 2014 143 14 281 559 0.34 [ 0.29, 0.38 ] 0.98 [ 0.96, 0.99 ]
Peter 2012a 85 1 102 26 0.45 [ 0.38, 0.53 ] 0.96 [ 0.81, 1.00 ]
Peter 2015 21 7 167 180 0.11 [ 0.07, 0.17 ] 0.96 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Diagnosis of TB against microbiological reference at Grade 1, CD4 > 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 5 Diagnosis of TB against microbiological reference at Grade 1, CD4 > 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 1 3 0 7 1.00 [ 0.03, 1.00 ] 0.70 [ 0.35, 0.93 ]
Lawn 2014a 1 4 27 132 0.04 [ 0.00, 0.18 ] 0.97 [ 0.93, 0.99 ]
Nakiyingi 2014 29 69 59 266 0.33 [ 0.23, 0.44 ] 0.79 [ 0.75, 0.84 ]
Peter 2015 26 38 49 159 0.35 [ 0.24, 0.47 ] 0.81 [ 0.74, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Diagnosis of TB against microbiological reference at Grade 1, CD4 < 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 6 Diagnosis of TB against microbiological reference at Grade 1, CD4 < 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 18 27 0 23 1.00 [ 0.81, 1.00 ] 0.46 [ 0.32, 0.61 ]
Lawn 2014a 63 9 44 130 0.59 [ 0.49, 0.68 ] 0.94 [ 0.88, 0.97 ]
Nakiyingi 2014 196 69 81 221 0.71 [ 0.65, 0.76 ] 0.76 [ 0.71, 0.81 ]
Peter 2015 38 30 59 123 0.39 [ 0.29, 0.50 ] 0.80 [ 0.73, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Diagnosis of TB against microbiological reference at Grade 1, CD4 > 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 7 Diagnosis of TB against microbiological reference at Grade 1, CD4 > 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 4 10 0 16 1.00 [ 0.40, 1.00 ] 0.62 [ 0.41, 0.80 ]
Lawn 2014a 15 7 48 185 0.24 [ 0.14, 0.36 ] 0.96 [ 0.93, 0.99 ]
Nakiyingi 2014 68 86 101 351 0.40 [ 0.33, 0.48 ] 0.80 [ 0.76, 0.84 ]
Peter 2015 41 50 85 222 0.33 [ 0.24, 0.41 ] 0.82 [ 0.76, 0.86 ]
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Test 8. Diagnosis of TB against microbiological reference at Grade 1, CD4 < 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 8 Diagnosis of TB against microbiological reference at Grade 1, CD4 < 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 15 20 0 14 1.00 [ 0.78, 1.00 ] 0.41 [ 0.25, 0.59 ]
Lawn 2014a 49 6 23 77 0.68 [ 0.56, 0.79 ] 0.93 [ 0.85, 0.97 ]
Nakiyingi 2014 157 52 39 136 0.80 [ 0.74, 0.85 ] 0.72 [ 0.65, 0.79 ]
Peter 2015 23 18 23 60 0.50 [ 0.35, 0.65 ] 0.77 [ 0.66, 0.86 ]
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Test 9. Diagnosis of TB against microbiological reference at Grade 1, CD4 > 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 9 Diagnosis of TB against microbiological reference at Grade 1, CD4 > 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 7 16 0 23 1.00 [ 0.59, 1.00 ] 0.59 [ 0.42, 0.74 ]
Lawn 2014a 29 10 54 226 0.35 [ 0.25, 0.46 ] 0.96 [ 0.92, 0.98 ]
Nakiyingi 2014 116 97 113 386 0.51 [ 0.44, 0.57 ] 0.80 [ 0.76, 0.83 ]
Peter 2015 51 58 98 250 0.34 [ 0.27, 0.42 ] 0.81 [ 0.76, 0.85 ]
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Test 10. Diagnosis of TB against microbiological reference at Grade 1, CD4 < 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 10 Diagnosis of TB against microbiological reference at Grade 1, CD4 < 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 12 14 0 7 1.00 [ 0.74, 1.00 ] 0.33 [ 0.15, 0.57 ]
Lawn 2014a 35 3 17 36 0.67 [ 0.53, 0.80 ] 0.92 [ 0.79, 0.98 ]
Nakiyingi 2014 109 41 27 101 0.80 [ 0.72, 0.86 ] 0.71 [ 0.63, 0.78 ]
Peter 2015 13 10 10 32 0.57 [ 0.34, 0.77 ] 0.76 [ 0.61, 0.88 ]
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Test 11. Diagnosis of TB against microbiological reference at Grade 2, CD4 > 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 11 Diagnosis of TB against microbiological reference at Grade 2, CD4 > 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 1 0 0 10 1.00 [ 0.03, 1.00 ] 1.00 [ 0.69, 1.00 ]
Lawn 2014a 1 0 27 136 0.04 [ 0.00, 0.18 ] 1.00 [ 0.97, 1.00 ]
Nakiyingi 2014 8 5 80 330 0.09 [ 0.04, 0.17 ] 0.99 [ 0.97, 1.00 ]
Peter 2012a 7 5 19 24 0.27 [ 0.12, 0.48 ] 0.83 [ 0.64, 0.94 ]
Peter 2015 14 13 61 184 0.19 [ 0.11, 0.29 ] 0.93 [ 0.89, 0.96 ]
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Test 12. Diagnosis of TB against microbiological reference at Grade 2, CD4 < 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 12 Diagnosis of TB against microbiological reference at Grade 2, CD4 < 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 14 14 3 36 0.82 [ 0.57, 0.96 ] 0.72 [ 0.58, 0.84 ]
Lawn 2014a 52 3 55 136 0.49 [ 0.39, 0.58 ] 0.98 [ 0.94, 1.00 ]
Nakiyingi 2014 128 15 149 275 0.46 [ 0.40, 0.52 ] 0.95 [ 0.92, 0.97 ]
Peter 2012a 58 26 49 78 0.54 [ 0.44, 0.64 ] 0.75 [ 0.66, 0.83 ]
Peter 2015 23 9 74 147 0.24 [ 0.16, 0.33 ] 0.94 [ 0.89, 0.97 ]
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Test 13. Diagnosis of TB against microbiological reference at Grade 1, CD4 > 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 13 Diagnosis of TB against microbiological reference at Grade 1, CD4 > 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 4 7 0 19 1.00 [ 0.40, 1.00 ] 0.73 [ 0.52, 0.88 ]
Lawn 2014a 12 1 51 191 0.19 [ 0.10, 0.31 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 20 8 149 429 0.12 [ 0.07, 0.18 ] 0.98 [ 0.96, 0.99 ]
Peter 2012a 21 15 38 47 0.36 [ 0.24, 0.49 ] 0.76 [ 0.63, 0.86 ]
Peter 2015 23 17 103 255 0.18 [ 0.12, 0.26 ] 0.94 [ 0.90, 0.96 ]
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Test 14. Diagnosis of TB against microbiological reference at Grade 1, CD4 < 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 14 Diagnosis of TB against microbiological reference at Grade 1, CD4 < 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 11 7 3 27 0.79 [ 0.49, 0.95 ] 0.79 [ 0.62, 0.91 ]
Lawn 2014a 41 2 31 81 0.57 [ 0.45, 0.69 ] 0.98 [ 0.92, 1.00 ]
Nakiyingi 2014 116 12 80 176 0.59 [ 0.52, 0.66 ] 0.94 [ 0.89, 0.97 ]
Peter 2012a 44 16 30 55 0.59 [ 0.47, 0.71 ] 0.77 [ 0.66, 0.87 ]
Peter 2015 14 5 32 76 0.30 [ 0.18, 0.46 ] 0.94 [ 0.86, 0.98 ]
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Test 15. Diagnosis of TB against microbiological reference at Grade 1, CD4 > 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 15 Diagnosis of TB against microbiological reference at Grade 1, CD4 > 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 7 7 0 32 1.00 [ 0.59, 1.00 ] 0.82 [ 0.66, 0.92 ]
Lawn 2014a 23 2 60 234 0.28 [ 0.18, 0.39 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 53 8 176 475 0.23 [ 0.18, 0.29 ] 0.98 [ 0.97, 0.99 ]
Peter 2012a 39 24 54 75 0.42 [ 0.32, 0.53 ] 0.76 [ 0.66, 0.84 ]
Peter 2015 25 21 124 287 0.17 [ 0.11, 0.24 ] 0.93 [ 0.90, 0.96 ]
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Test 16. Diagnosis of TB against microbiological reference at Grade 1, CD4 < 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 16 Diagnosis of TB against microbiological reference at Grade 1, CD4 < 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 8 7 3 14 0.73 [ 0.39, 0.94 ] 0.67 [ 0.43, 0.85 ]
Lawn 2014a 30 1 22 38 0.58 [ 0.43, 0.71 ] 0.97 [ 0.87, 1.00 ]
Nakiyingi 2014 83 12 53 130 0.61 [ 0.52, 0.69 ] 0.92 [ 0.86, 0.96 ]
Peter 2012a 26 7 14 27 0.65 [ 0.48, 0.79 ] 0.79 [ 0.62, 0.91 ]
Peter 2015 12 1 11 44 0.52 [ 0.31, 0.73 ] 0.98 [ 0.88, 1.00 ]
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Test 17. Diagnosis of TB against microbiological reference at Grade 1: inpatients.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 17 Diagnosis of TB against microbiological reference at Grade 1: inpatients
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 19 37 0 37 1.00 [ 0.82, 1.00 ] 0.50 [ 0.38, 0.62 ]
Lawn 2014a 64 13 72 264 0.47 [ 0.38, 0.56 ] 0.95 [ 0.92, 0.97 ]
Nakiyingi 2014 166 78 80 227 0.67 [ 0.61, 0.73 ] 0.74 [ 0.69, 0.79 ]
Peter 2012a 77 43 39 82 0.66 [ 0.57, 0.75 ] 0.66 [ 0.57, 0.74 ]
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Test 18. Diagnosis of TB against microbiological reference at Grade 2: inpatients.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 18 Diagnosis of TB against microbiological reference at Grade 2: inpatients
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Andrews 2014 16 14 3 60 0.84 [ 0.60, 0.97 ] 0.81 [ 0.70, 0.89 ]
Lawn 2014a 53 3 83 274 0.39 [ 0.31, 0.48 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 114 19 132 287 0.46 [ 0.40, 0.53 ] 0.94 [ 0.90, 0.96 ]
Peter 2012a 58 31 58 94 0.50 [ 0.41, 0.59 ] 0.75 [ 0.67, 0.82 ]
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Test 19. Diagnosis of TB against microbiological reference at Grade 1: outpatients.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 19 Diagnosis of TB against microbiological reference at Grade 1: outpatients
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nakiyingi 2014 60 63 61 261 0.50 [ 0.40, 0.59 ] 0.81 [ 0.76, 0.85 ]
Peter 2015 68 81 113 307 0.38 [ 0.30, 0.45 ] 0.79 [ 0.75, 0.83 ]
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Test 20. Diagnosis of TB against microbiological reference at Grade 2: outpatients.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 20 Diagnosis of TB against microbiological reference at Grade 2: outpatients
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nakiyingi 2014 22 2 99 322 0.18 [ 0.12, 0.26 ] 0.99 [ 0.98, 1.00 ]
Peter 2015 41 27 140 361 0.23 [ 0.17, 0.29 ] 0.93 [ 0.90, 0.95 ]
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Test 21. Diagnosis of TB with LAM at Grade 2 (among studies comparing with smear).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 21 Diagnosis of TB with LAM at Grade 2 (among studies comparing with smear)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 53 3 83 274 0.39 [ 0.31, 0.48 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 136 14 231 559 0.37 [ 0.32, 0.42 ] 0.98 [ 0.96, 0.99 ]
Peter 2012a 58 31 58 94 0.50 [ 0.41, 0.59 ] 0.75 [ 0.67, 0.82 ]
Peter 2015 22 9 67 183 0.25 [ 0.16, 0.35 ] 0.95 [ 0.91, 0.98 ]
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Test 22. Diagnosis of TB with smear (among studies comparing with LAM).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 22 Diagnosis of TB with smear (among studies comparing with LAM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 26 0 110 277 0.19 [ 0.13, 0.27 ] 1.00 [ 0.99, 1.00 ]
Nakiyingi 2014 128 0 239 573 0.35 [ 0.30, 0.40 ] 1.00 [ 0.99, 1.00 ]
Peter 2012a 60 5 56 120 0.52 [ 0.42, 0.61 ] 0.96 [ 0.91, 0.99 ]
Peter 2015 39 13 50 179 0.44 [ 0.33, 0.55 ] 0.93 [ 0.89, 0.96 ]
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Test 23. Diagnosis of TB with combination of LAM at Grade 2 with smear.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 23 Diagnosis of TB with combination of LAM at Grade 2 with smear
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 64 3 72 274 0.47 [ 0.38, 0.56 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 197 14 170 559 0.54 [ 0.48, 0.59 ] 0.98 [ 0.96, 0.99 ]
Peter 2012a 82 34 34 91 0.71 [ 0.62, 0.79 ] 0.73 [ 0.64, 0.80 ]
Peter 2015 50 20 39 173 0.56 [ 0.45, 0.67 ] 0.90 [ 0.84, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Diagnosis of TB with LAM at Grade 2 (among studies comparing with Xpert®).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 24 Diagnosis of TB with LAM at Grade 2 (among studies comparing with Xpert )
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 53 3 79 278 0.40 [ 0.32, 0.49 ] 0.99 [ 0.97, 1.00 ]
Nakiyingi 2014 50 3 53 102 0.49 [ 0.39, 0.59 ] 0.97 [ 0.92, 0.99 ]
Peter 2015 19 18 73 178 0.21 [ 0.13, 0.30 ] 0.91 [ 0.86, 0.94 ]
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Test 25. Diagnosis of TB with Xpert® (among studies comparing with LAM).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 25 Diagnosis of TB with Xpert (among studies comparing with LAM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 35 1 97 280 0.27 [ 0.19, 0.35 ] 1.00 [ 0.98, 1.00 ]
Nakiyingi 2014 78 2 25 103 0.76 [ 0.66, 0.84 ] 0.98 [ 0.93, 1.00 ]
Peter 2015 70 14 22 182 0.76 [ 0.66, 0.84 ] 0.93 [ 0.88, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. Diagnosis of TB with combination of LAM at Grade 2 with Xpert®.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 26 Diagnosis of TB with combination of LAM at Grade 2 with Xpert
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lawn 2014a 71 4 61 277 0.54 [ 0.45, 0.62 ] 0.99 [ 0.96, 1.00 ]
Nakiyingi 2014 88 5 15 100 0.85 [ 0.77, 0.92 ] 0.95 [ 0.89, 0.98 ]
Peter 2015 72 27 20 169 0.78 [ 0.68, 0.86 ] 0.86 [ 0.81, 0.91 ]
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Test 27. Screening for TB against microbiological reference at Grade 1: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 27 Screening for TB against microbiological reference at Grade 1: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 33 45 95 584 0.26 [ 0.18, 0.34 ] 0.93 [ 0.91, 0.95 ]
Drain 2014a 17 28 43 254 0.28 [ 0.17, 0.41 ] 0.90 [ 0.86, 0.93 ]
Drain 2014b 22 21 32 245 0.41 [ 0.28, 0.55 ] 0.92 [ 0.88, 0.95 ]
Lawn 2012a 24 6 67 419 0.26 [ 0.18, 0.37 ] 0.99 [ 0.97, 0.99 ]
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Test 28. Screening for TB against microbiological reference at Grade 2: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 28 Screening for TB against microbiological reference at Grade 2: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 24 21 31 393 0.44 [ 0.30, 0.58 ] 0.95 [ 0.92, 0.97 ]
Drain 2014b 15 16 39 250 0.28 [ 0.16, 0.42 ] 0.94 [ 0.90, 0.97 ]
LaCourse 2015 0 13 3 250 0.0 [ 0.0, 0.71 ] 0.95 [ 0.92, 0.97 ]
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Test 29. Screening for TB against composite reference at Grade 1: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 29 Screening for TB against composite reference at Grade 1: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Drain 2014a 23 22 69 228 0.25 [ 0.17, 0.35 ] 0.91 [ 0.87, 0.94 ]
Drain 2014b 26 17 42 235 0.38 [ 0.27, 0.51 ] 0.93 [ 0.89, 0.96 ]
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Test 30. Screening for TB against composite reference at Grade 2: all participants.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 30 Screening for TB against composite reference at Grade 2: all participants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 36 9 64 360 0.36 [ 0.27, 0.46 ] 0.98 [ 0.95, 0.99 ]
LaCourse 2015 0 13 5 248 0.0 [ 0.0, 0.52 ] 0.95 [ 0.92, 0.97 ]
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Test 31. Screening for TB against microbiological reference at Grade 1, CD4 > 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 31 Screening for TB against microbiological reference at Grade 1, CD4 > 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 6 22 46 328 0.12 [ 0.04, 0.23 ] 0.94 [ 0.91, 0.96 ]
Lawn 2012a 1 2 27 162 0.04 [ 0.00, 0.18 ] 0.99 [ 0.96, 1.00 ]
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Test 32. Screening for TB against microbiological reference at Grade 1, CD4 < 200.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 32 Screening for TB against microbiological reference at Grade 1, CD4 < 200
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 27 23 49 254 0.36 [ 0.25, 0.47 ] 0.92 [ 0.88, 0.95 ]
Lawn 2012a 23 3 40 259 0.37 [ 0.25, 0.50 ] 0.99 [ 0.97, 1.00 ]
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Test 33. Screening for TB against microbiological reference at Grade 1, CD4 > 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 33 Screening for TB against microbiological reference at Grade 1, CD4 > 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 14 32 78 487 0.15 [ 0.09, 0.24 ] 0.94 [ 0.91, 0.96 ]
Drain 2014b 6 10 19 186 0.24 [ 0.09, 0.45 ] 0.95 [ 0.91, 0.98 ]
Lawn 2012a 9 4 51 325 0.15 [ 0.07, 0.27 ] 0.99 [ 0.97, 1.00 ]
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Test 34. Screening for TB against microbiological reference at Grade 1, CD4 < 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 34 Screening for TB against microbiological reference at Grade 1, CD4 < 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 19 13 17 217 0.53 [ 0.35, 0.70 ] 0.94 [ 0.91, 0.97 ]
Drain 2014b 15 8 12 32 0.56 [ 0.35, 0.75 ] 0.80 [ 0.64, 0.91 ]
Lawn 2012a 15 1 16 214 0.48 [ 0.30, 0.67 ] 1.00 [ 0.97, 1.00 ]
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Test 35. Screening for TB against microbiological reference at Grade 1, CD4 > 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 35 Screening for TB against microbiological reference at Grade 1, CD4 > 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 23 40 91 545 0.20 [ 0.13, 0.29 ] 0.93 [ 0.91, 0.95 ]
Lawn 2012a 12 4 61 376 0.16 [ 0.09, 0.27 ] 0.99 [ 0.97, 1.00 ]
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Test 36. Screening for TB against microbiological reference at Grade 1, CD4 < 50.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 36 Screening for TB against microbiological reference at Grade 1, CD4 < 50
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 10 5 4 37 0.71 [ 0.42, 0.92 ] 0.88 [ 0.74, 0.96 ]
Lawn 2012a 12 1 6 45 0.67 [ 0.41, 0.87 ] 0.98 [ 0.88, 1.00 ]
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Test 37. Screening for TB against microbiological reference at Grade 2, CD4 > 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 37 Screening for TB against microbiological reference at Grade 2, CD4 > 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 8 2 16 233 0.33 [ 0.16, 0.55 ] 0.99 [ 0.97, 1.00 ]
Drain 2014b 4 6 21 190 0.16 [ 0.05, 0.36 ] 0.97 [ 0.93, 0.99 ]
LaCourse 2015 0 11 3 200 0.0 [ 0.0, 0.71 ] 0.95 [ 0.91, 0.97 ]
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Test 38. Screening for TB against microbiological reference at Grade 2, CD4 < 100.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 38 Screening for TB against microbiological reference at Grade 2, CD4 < 100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 14 18 15 148 0.48 [ 0.29, 0.67 ] 0.89 [ 0.83, 0.93 ]
Drain 2014b 10 8 17 32 0.37 [ 0.19, 0.58 ] 0.80 [ 0.64, 0.91 ]
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88Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 39. Screening for TB against microbiological reference at Grade 1: outpatients.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 39 Screening for TB against microbiological reference at Grade 1: outpatients
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Balcha 2014 33 45 95 584 0.26 [ 0.18, 0.34 ] 0.93 [ 0.91, 0.95 ]
Drain 2014a 17 28 43 254 0.28 [ 0.17, 0.41 ] 0.90 [ 0.86, 0.93 ]
Drain 2014b 22 21 32 245 0.41 [ 0.28, 0.55 ] 0.92 [ 0.88, 0.95 ]
Lawn 2012a 24 6 67 419 0.26 [ 0.18, 0.37 ] 0.99 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 40. Screening for TB with LAM at Grade 2 (among studies comparing with smear microscopy).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 40 Screening for TB with LAM at Grade 2 (among studies comparing with smear microscopy)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 24 21 31 395 0.44 [ 0.30, 0.58 ] 0.95 [ 0.92, 0.97 ]
Drain 2014b 15 16 39 250 0.28 [ 0.16, 0.42 ] 0.94 [ 0.90, 0.97 ]
LaCourse 2015 0 13 3 250 0.0 [ 0.0, 0.71 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 41. Screening for TB with smear microscopy (among studies comparing with LAM).
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 41 Screening for TB with smear microscopy (among studies comparing with LAM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 29 6 26 410 0.53 [ 0.39, 0.66 ] 0.99 [ 0.97, 0.99 ]
Drain 2014b 8 2 46 264 0.15 [ 0.07, 0.27 ] 0.99 [ 0.97, 1.00 ]
LaCourse 2015 0 2 3 263 0.0 [ 0.0, 0.71 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. Screening for TB with the combination of LAM (Grade 2) and smear microscopy.
Review: Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults
Test: 42 Screening for TB with the combination of LAM (Grade 2) and smear microscopy
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bjerrum 2015 34 26 21 390 0.62 [ 0.48, 0.75 ] 0.94 [ 0.91, 0.96 ]
Drain 2014b 19 18 35 266 0.35 [ 0.23, 0.49 ] 0.94 [ 0.90, 0.96 ]
LaCourse 2015 0 15 3 248 0.0 [ 0.0, 0.71 ] 0.94 [ 0.91, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. LF-LAM pooled sensitivity and specificity for TB diagnosis, by grade
Type of
analysis
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Table 1. LF-LAM pooled sensitivity and specificity for TB diagnosis, by grade (Continued)
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Abbreviations: Crl: credible interval; LF-LAM: lateral flow urine lipoarabinomannan assay; TB: tuberculosis.
1For the composite reference test, sensitivity ranged from 23% to 60% and specificity ranged from 78% to 96% at grade 1; sensitivity
ranged from 11% to 45% and specificity ranged from 96% to 98% at grade 2.
2For the outpatient setting, sensitivity ranged from 38% to 50% and specificity ranged from 79% to 81% at grade 1; sensitivity ranged
from 18% to 23% and specificity ranged from 93% to 96% at grade 2.
3Sensitivity of smear was 19%, compared to 47% for LAM, and 54% for the combination of smear and LAM. Specificity of smear was
100%, compared to 95% for LAM, and 95% for the combination of smear and LAM.
Table 2. Comparison of mortality in LF-LAM-positive and LF-LAM-negative participants




Balcha 2014 757outpatients (screening) 148 TB cases 20% (7/35) 3% (3/113)
Bjerrum 2015 469outpatients (screening) 469 enrollees 49% (22/45) 14% (59/424)
55 TB cases 54% (13/24) 16% (5/31)
39 TB starting treatment 32% (5/16) 4% (1/23)
Drain 2015 90 outpatients started on
TB therapy
Baseline 31% (9/29); AHR 1.41 31% (16/61)
2-month LF-LAM (grade
2)
50% (4/8) AHR 5.58 19% (12/65)
Lawn 2012c 535 ART enrollees (screen-
ing)
59 TB cases 22% (5/23) 0% (0/36)
Manabe 2014 351 hospitalized (diagno-
sis)
351 enrollees 28% (38/134) 17% (37/217)
145 TB cases 28% (25/90) 13% (7/55)
185with no evidence ofTB 34% (12/35) 19% (28/150)
Peter 2015 583 outpatients (diagnosis) 583 enrollees 25% (9/32) 11% (40/361)
123 TB cases 35% (6/17) 14% (15/106)
Abbreviations: AHR: adjusted hazard ratio; ART: antiretroviral therapy; LF-LAM: lateral flow urine lipoarabinomannan assay; TB:
tuberculosis.
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A P P E N D I C E S
Appendix 1. Minimum specifications for a point-of-care TB diagnostic test
Test specification Minimum required value
Medical decision Treatment initiation
Sensitivity: adults
(for pulmonary TB only;
regardless of HIV status)
Pulmonary TB
• 95% for smear positive, culture positive
• 60% to 80% for smear negative, culture positive




regardless of HIV status)
• 80% compared to culture of any specimen and
• 60% of probable TB (noting problem of lack of a gold
standard)
Specificity: adults • 95% compared to culture
Specificity: children • 90% for culture-negative probable TB (noting problem of
lack of a gold standard)
• 95% compared to culture
Time to results 3 hours maximum (patient must receive results the same day)
(desirable would be < 15 minutes)
Throughput 20 tests/day minimum, by one laboratory technician
Specimen type Adults: urine, oral, breath, venous blood, sputum
(desired: non sputum-based sample type and use of finger prick
instead of venous blood)
Children: urine, oral, capillary blood (finger or heel prick)
Sample preparation • 3 steps maximum
• Safe: biosafety level 1
• Ability to use approximate volumes (that is, no need for
precise pipetting)
• Preparation that is not highly time sensitive
Number of samples 1 sample per test
Readout • Easy-to-read, unambiguous, simple “yes”, “no”, or
“invalid” answer
• Readable for at least one hour
Waste disposal • Simple burning or sharps disposal; no glass component
• Environmentally acceptable disposal
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(Continued)
Controls • Positive control included in test kit
• Quality control simpler and easier than with sputum smear
microscopy
Reagents • All reagents in self-contained kit
• Kit contains sample collection device and water (if needed)
Storage/stability required • Shelf life of 24 months, including reagents
• Stable at 30°C, and at higher temperatures for shorter time
periods
• Stable in high humidity environments
Instrumentation • If instrument needed, no maintenance required
• Instrument works in tropical conditions
• Acceptable replacement cost
• Fits in backpack
• Shock resistant
Power requirement Can work on battery
Training • 1 day maximum training time
• Can be performed by any health worker
< USD 10 per test after scale-upCost
Copyright © Batz 2011; reproduced with permission.
Abbreviations: TB, tuberculosis; USD, United States Dollar.
Appendix 2. Detailed search strategies
MEDLINE (PubMed) search history
Search Query
#9 Search (#3) AND (#7) AND #8)
#8 Search test OR assay OR antigen OR Ag OR lateral flow assay*OR urine antigen OR point of care Field: Title/
Abstract
#7 Search (#4) OR #5) OR #6
#6 Search LAM; Field: Title/Abstract
#5 Search “lipoarabinomannan” [Supplementary Concept]
#4 Search lipoarabinomannan ; Field: Title/Abstract
#3 Search (#1) OR #2)
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(Continued)
#2 Search tuberculosis Or TB Field: Title/Abstract
#1 Search (“Tuberculosis”[Mesh]) OR “Mycobacterium tuberculosis”[Mesh]
˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙
Web of Science Core Collection - Indexes: SCI-EXPANDED, CPCI-S, Biosis previews
You searched for: TOPIC: (tuberculosis OR TB OR mycobacterium) AND TOPIC: (lipoarabinomannan OR LAM) AND TOPIC:
(10. test OR assay OR antigen OR Ag OR lateral flow assay*OR urine antigen OR point of care) ...More TOPIC: (tuberculosis OR
TB ORmycobacterium) AND TOPIC: (lipoarabinomannan OR LAM) AND TOPIC: ( test OR assay OR antigen OR Ag OR lateral
flow assay*OR urine antigen OR point of care)
˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙
SCOPUS
( TITLE-ABS-KEY ( tuberculosis OR tb ) AND TITLE-ABS-KEY ( lipoarabinomannan OR lam ) AND PUBYEAR > 2013 ) AND
( test OR diagnos* OR urine OR assay )
Database: EMBASE search strategy
--------------------------------------------------------------------------------
1 tuberculosis.mp. or tuberculosis/ or Mycobacterium tuberculosis/
2 lipoarabinomannan.mp. or lipoarabinomannan/
3 LAM.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manu-
facturer, device trade name, keyword]
4 2 or 3
5 1 and 4
6 (test or assay or antigen or Ag or lateral flow assay* or urine antigen or point of care).mp
7 4 and 5
CIDG Specialized Register, LILACS, Medion, Proquest dissertations, Current Controlled trials, WHO trials register
Tuberculosis AND ( lipoarabinomannan OR LAM)
Appendix 3. Data collection form
Lateral flow urine lipoarabinomannan assay for diagnosing active tuberculosis in people living with HIV
Data form
1 First author
2 Corresponding author and email
3 Title of study
4 Publication status of study 1. Published
2. Unpublished, what is the anticipated
study completion date?
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(Continued)
5 For the diagnosis of pulmonary TB, what
reference standard was used to identify TB
and not TB?
1. Sputum: solid culture
2. Sputum: liquid culture
3. Sputum: both solid and liquid culture
4. Nucleic acid amplification test, specify
6. Other, specify
6 Was sputum induction performed for in-
dividuals unable to produce expectorated
sputum?
1. Yes, specify N/% ( ) requiring spu-
tum induction
2. No
7 Were patients without sputum specimens
(for example, no expectorated, no induced
sputum) included in this study?
1. Yes, specify N/% of patients included
without sputum
2. No, specify N/% of patients excluded
due to lack of sputum
8 Were non-pulmonary specimens evaluated
to allow diagnosis of extrapulmonary TB?
1. All participants received testing of non-
pulmonary samples, please specify sites/flu-
ids:
2. Some participants received testing of
non-pulmonary samples, please specify
which patients were tested, and sites/fluids:
3. Extrapulmonary TB was not evaluated
6. Other, please specify:
9 For the diagnosis of extrapulmonary TB,
what tests were used to identify TB and not
TB (circle all that apply)?
1. Solid culture
2. Liquid culture
3. Both solid and liquid culture
4. Nucleic acid amplification test, specify
6. Other, specify
8. Not applicable, extrapulmonary TB was
not evaluated
10 How many sputum specimens were ob-
tained in order to detect pulmonary TB?
Mean (standard deviation (SD)) number of
specimens per patient =
Not applicable
11 If applicable, how many specimens from
body sites or fluids other than sputum were
obtained in order to detect extrapulmonary
TB?
Mean (SD) number of specimens per pa-
tient =
Not applicable
12 Inwhich country or countrieswas the study
conducted?
Please list all countries:
13 What was the clinical setting of the study? 1. Outpatient
2. Inpatient
3. Both out-patient and in-patient
6. Other, describe:
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(Continued)
13a How would you describe the health facility
where the study took place?
1. Primary care clinic, stand alone




14 Please select the statement that best de-
scribes the selection of participants into
your study
1. HIV-positive participants with signs or
symptoms suggestive of active TB were
tested using LF-LAM. Please provide study
definition of ‘signs and symptoms’:
2. A predetermined target population of
HIV-positive individuals, with or without
signs or symptoms of active TB, were tested
using LF-LAM: please specify target popu-
lation
3. Both 1 and 2
4. Neither 1 nor 2. This is what we did:
15 What was the manner of participant selec-





16 Was LF-LAM performed on fresh or stored
urine
1. Fresh
2. Stored, specify type of storage (e.g.
frozen)
3. Both fresh and stored
17 Which package insert reference card was
used to grade LF-LAM results in the study?
1. “Original”: 5 grades, prior to Jan 2014
2. “New”: 4 grades, after Jan 2014 date
9. I do not know
18 What specific grade LF-LAM value was





9. I do not know
18 Was data collected on alternative thresholds
(grades) to define positivity
1. Yes, please specify
2. No
19 Was LF-LAM result interpreted without




20 Was the reference standard result inter-
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(Continued)
21 Did more than one individual read the LF-
LAM result?
1. Yes: please specify kappa or other mea-
sure of correlation
2. No
22 Were clinical outcomes evaluated, such as
time to diagnosis or mortality?
1. Yes, If yes, please list the outcomes
2. No
23 Were there any LF-LAM results that were
invalid (no bar in control window)?
1. Yes, if yes, please list number of invalid
tests:
Please list if invalid tests were repeated: a)
Yes b) No
2. No
24 Were any LF-LAM results uninterpretable
for other reasons?
1. Yes, if yes please list number of uninter-
pretable tests and reasons:
2. No
25 What was themedian ormean CD4 of par-
ticipants?
Median (IQR) or mean (SD)
26 What percentage of participants was fe-
male?
27 What was the median or mean age of par-
ticipants?
Median (IQR) or mean (SD)
Abbreviations: IQR, interquartile range; SD, standard deviation.
Table 1a. Microbiological reference standard
TB is defined as positive culture or NAAT from sputum or any body fluid or site.
Not TB is defined as negative cultures or NAATs from sputum or any body fluid or site.










Please check box if data not available
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Table 1b. Composite reference standard
TB defined as satisfying at least one of the following components:
(a) a positive mycobacterial culture or NAAT from any body fluid or site; (b) positive sputum smear microscopy; or (c) a clinical
diagnosis of TB, in which the patient was started on TB treatment by a health care provider, and, after at least one month of follow-
up, was classified as ’TB’ or ’Not TB’.
’Not TB’ defined as
(a) patients had no positive culture, NAAT, or smear for TB AND
(b) patients were not started on anti-TB treatment by health care providers
(c) patients were alive at one month of follow-up and were clinically classified by a health care provider as Not TB
People who do not meet the criteria for ’TB’ or ’Not TB’ based on these definitions will be excluded as ‘unclassifiable’.




















Please fill in the cells in the following table for study participants stratified by CD4 count
99Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Please check box if CD4 stratified data are not available
For Tables 2a through 5a, use the microbiological reference standard
Table 2a. CD4 > 200
LAM result
Grade






Table 3a. CD4 101 to 200
LAM result
Grade






Table 4a. CD4 51 to 100
LAM result
Grade






Table 5a. CD4 ≤ 50
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Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled?
We scored ’yes’ if the study enrolled a consecutive or random sample of eligible participants; ’no’ if the study selected participants by
convenience; and ’unclear’ if the study did not report the manner of participant selection or we could not tell.
Signalling question 2: Was a case-control design avoided?
We scored ’yes’ to all included studies given that we are excluding case-control study designs.
Signalling question 3: Did the study avoid inappropriate exclusions?
We scored ’yes’ to studies which included: a) all HIV-positive participants regardless of CD4 count and b) participants who were
unable to produce sputum (expectorated or induced). We scored ’no’ if studies excluded participants on the basis of CD4 count or
the inability to produce sputum (no attempts at sputum induction). We also scored ’no’ if studies excluded patients presumed to have
extrapulmonary TB. We scored ’unclear’ if we could not tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We were interested in how LF-LAM performs in patients whose urine specimens were evaluated as they would be in routine practice.
We expected to score most studies as ’low concern’ since we planned to determine test accuracy separately for TB screening and TB
diagnosis.
For LF-LAM used as a TB diagnostic test, we scored ’high concern’ if the study participants did not resemble people with presumed
TB; ’low concern’ if the study population did resemble a population with presumed TB, and ’unclear concern’, if we could not tell.
For LF-LAM used as a TB screening test, we have defined ’screening’ for active TB in accordance with World Health Organization
(WHO) guidance, as “the systematic identification of people with suspected active TB, in a predetermined target group, using tests,
examinations or other procedures that can be applied rapidly (WHOTuberculosis Screening 2013)”.We scored ’low concern’ for studies
in which the LF-LAM was performed uniformly within the predetermined study target populations of HIV-infected individuals, ’high
concern’ if LF-LAM was not performed uniformly within the predetermined study target populations of HIV-infected individuals, and
’unclear concern’ if we could not tell.
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Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard?
We answered ’yes’ if the study interpreted the result of LF-LAM blinded to the result of the reference standard; we answered ’no’ if the
study did not interpret the result of LF-LAM blinded to the result of the reference standard. We answered ’yes’ for studies in which
LF-LAM was performed on fresh specimens, since reference standard results would be unavailable at the time of test interpretation.
We answered ’unclear’ if stored specimens were tested or we could not tell if the index test results were interpreted without knowledge
of the reference standard results.
Signalling question 2: if a LF-LAM threshold was used to define positivity, was it prespecified?
We answered ’yes’ if the threshold was prespecified, ’no’ if the threshold was not prespecified, and ’unclear’ if we could not determine
if the threshold was prespecified or not.
Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question?
If index test methods vary from those specified in the review question, concerns about applicability may exist. We judged ’high concern’
if the test procedure was inconsistent with the manufacturer recommendations, ’low concern’ if the test procedure was consistent with
the manufacturer recommendations, and ’unclear concern’ if we could not tell.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
We considered this question separately for each reference standard.
a) Microbiological reference standard
HIV-infectedTBpatientsmay have pulmonary TB, extrapulmonary TB, or both pulmonary and extrapulmonary TB. Amicrobiological
reference standard, primarily culture, is considered the gold standard for TB. Due to the difficulties in diagnosing HIV-associated TB,
it is recommended that multiple cultures from sputum and other specimens be evaluated.
We answered ’yes’ when appropriate specimens were obtained for the diagnosis of HIV-associated TB. For presumed pulmonary TB,
sputum specimens should be obtained for culture, NAAT, or both culture and NAAT. If the patient cannot produce sputum, induced
sputum should be performed. For presumed extrapulmonary TB, specimens should be consistent with Standard 4 of the International
Standards for TB Care which states: “For all patients, including children, suspected of having extrapulmonary tuberculosis, appropriate
specimens from the suspected sites of involvement should be obtained for microbiological and histological examination” (TB CARE I
2014). We answered yes if multiple specimens were collected from different sites for extrapulmonary TB. An Xpert®MTB/RIF test is
recommended as the preferred initial microbiological test for suspected TBmeningitis because of the need for a rapid diagnosis“. We also
answered ’yes’ if studies followed a standardized approach of collecting appropriate specimens from ”suspected sites of involvement“,
for example, blood or lymph nodes on all patients.
We answered ’no’ when the reference standard was restricted to sputum specimens or the reference standard was restricted to extrapul-
monary specimens (for example, urine, blood, etc.). We also answered ’no’ if a consistent approach was not followed for all patients
(for example, some but not all patients with presumed TB lymphadenitis receive lymph node tissue sampling). We answered ’unclear’
if we could not tell.
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b) Composite reference standard
Considerable uncertainty surrounds a clinical diagnosis of TB. Therefore, a reference standard that uses clinical TB (in culture-negative
patients) is considered a lower quality reference standard and may incorrectly classify patients without TB disease as having TB disease.
We scored ’unclear’ for all studies that evaluated a combination of microbiological tests or clinical features to confirm TB.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We answered ’yes’ if the study interpreted the result of the reference standard blinded to the result of LF-LAM, or if the reference
standard result was reported on an automated instrument; ’no’ if the study did not interpret the result of the reference standard blinded
to the result of LF-LAM, and ’unclear’ if we could not tell.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
In general, we thought there was low concern for almost included studies based on the current definitions of the reference standard. We
judged ’high concern’ if included studies did not speciate mycobacteria isolated in culture, ’low concern’ if speciation was performed,
and ’unclear’ if we could not tell. We also judged high concern if there was no protocol to ensure a minimum standard of testing with
a reference standard.
Domain 4: Flow and timing
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and reference standard?
We expected urine specimens for LF-LAM and the reference standards to be obtained at the same time and answered ’yes’ for all studies
that meet this criterion, or if index and reference standard tests were performed on specimens collected no greater than seven days
apart. We chose seven days as a time period during which either treatment of TB or natural progression of TB without treatment could
impact test results. We answered ’no’ if specimens were collected for index and reference standard tests greater than seven days apart,
and ’unclear’ if we could not tell.
Signalling question 2: did all patients receive the same reference standard?
We considered this question separately for each reference standard.
a) Microbiological reference standard
We answered ’yes’ if all participants in the study received the reference standard to confirm TB; ’no’ if not all patients received the
reference standard to confirm TB, and ’unclear’ if we could not tell.
b) Composite reference standard
We scored ’unclear’ for all studies because, for a given study, it is unlikely that we will know if all participants received the same
component tests and if these component tests were interpreted and combined in a fixed way for all participants.
Signalling question 3: were all patients included in the analysis?
We determined the answer to this question by comparing the number of participants enrolled in the study with the number of
participants included in the two-by-two tables. We answered ’yes’ if all participants enrolled in the study were tested with results
presented and accounted for. We answered ’no’ if participants meeting enrolment criteria were not tested or results were not presented,
and ’unclear’ if we could not tell.
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Appendix 5. Statistical appendix
We list here two types of WinBUGS programs used to fit the bivariate meta-analysis models in this review: i) a program for estimating
the accuracy of the index test (T2), ii) a program for estimating the accuracy of an alternative test (T1) and a composite test (T3)
based on the combination of the index and the alternative tests. In the subsections below, we first describe the likelihood and prior
distribution for each type of model followed by the WinBUGS program.
As is usual with Bayesian models, initial values must be provided for all unknown parameters. For all programs, we selected three
independent sets of initial values for most parameters using the in-built gen.inits() function within WinBUGS. The Gelman-Rubin
statistic within the WinBUGS program was used to assess convergence. We did not observe any convergence problems for the analyses
presented. We treated the first 3000 iterations as burn-in iterations and dropped them.We obtained summary statistics based on a total
of 15,000 iterations resulting from the three separate chains.
A. Estimation of index test accuracy
Notation: in the i-th study the cells in the cross-tabulation between the index and reference tests are denoted by TPi , FPi , TNi , FNi .
The sensitivity in i-th study is denoted by sei and the specificity by spi .
We denote the Binomial probability distributionwith sample sizeN and probability p as Binomial(p,N), the BivariateNormal probability
distribution with mean vector µ and variance-covariance matrix S as BVN(mu, S), the univariate Normal distribution with meanm and
variance s by N(m, s) and the Uniform probability distribution between a and b by Uniform(a,b). Note that logit refers to log odds.
Likelihood:
Within studies:
TPi ~ Binomial(sei , TPi + FNi ), and
TNi ~ Binomial(spi , TNi + FPi )
Between studies:
The bivariate vector (logit(sei ), logit(spi )) ~ BVN(mu = (mu1, mu2), S) where
S is a 2 X 2 matrix with entries
S[1,1] = variance of logit(sei ) = sigma1
2,
S[2,2] = variance of logit(spi ) = sigma2
2 and
S[1,2] = S[2,1] = covariance between logit(sei ) and logit(spi ) = rho × sigma1 × sigma2
and rho is the correlation between logit(sei ) and logit(spi ) across studies.
The pooled sensitivity is given by 1/(1+exp(-mu1)), and the pooled specificity is given by 1/(1+exp(-mu2)).
Prior distributions:
mu1 and mu2 ~ N(m=0, s=4),
rho ~ Uniform(-1, 1)
(1/ sigma1
2) and (1/ sigma2
2) ~ Gamma(shape=2, rate=0.5)
A.1 WinBUGS program for estimating a bivariate hierarchical meta-analysis model for sensitivity and specificity of the index
test.
Observed data must be provided for L (the number of studies), and TP, FN, FP and TN in each study.
--------------------------------------------------------------------------------------------------------------------------------
model {
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T[1:2,1:2]<-inverse(S[1:2,1:2])





# prec is the between-study precision in the logit(sensitivity) and logit(specificity)










B. Estimation of the accuracy of an alternative test and a composite test
Notation: In the i-th study the four cells in the cross-tabulation between the index and alternative tests are denoted by T12˙Di among
disease positive and by T12˙NDi among disease negative. The sensitivity and specificity of the alternative test in i-th study are denoted
by se1i and sp1i , respectively. The sensitivity and specificity of the index test in i-th study are denoted by se2i and sp2i , respectively.
The sensitivity and specificity of the composite based on the index and the alternative tests in i-th study are denoted by se3i and sp3i ,
respectively.
We denote the Multinomial probability distribution with sample size N and probability p as Multinomial(p,N). For other probability
distributions we use the same notation as for the previous section.
Likelihood:
Within studies:
T12˙Di ~ Multinomial(pDi , Di ), and
T12˙NDi ~ Multinomial(pNDi , NDi )
The multinomial probabilities can be expressed in terms of the sensitivities and specificities of T1 and T2 and the covariance between
T1 and T2 in the disease positive as follows:
pDi [1] = se1i * se2i + covs[i] # P(t1=1, t2=1 | D=1)
pDi [2] = se1i * (1- se2i ) - covs[i] # P(t1=1, t2=0 | D=1)
pDi [3] = (1- se1i ) * se2i - covs[i] # P(t1=0, t2=1 | D=1)
pDi [4] = (1- se1i ) * (1- se2i ) + covs[i] # P(t1=0, t2=0 | D=1)
pNDi [1] = sp1i * sp2i # P(t1=1, t2=1 | D=0)
pNDi [2] = sp1i * (1- sp2i ) # P(t1=1, t2=0 | D=0)
pNDi [3] = (1- sp1i ) * sp2i # P(t1=0, t2=1 | D=0)
pNDi [4] = (1- sp1i ) * (1- sp2i ) # P(t1=0, t2=0 | D=0)
The sensitivity and specificity of the index test can be expressed in terms of the sensitivities and specificities of the composite and
alternative tests. Doing so allows us to estimate the pooled sensitivity and specificity of the composite and alternative tests. The form
of the between-studies likelihoods for the accuracy parameters of the composite test and the alternative test, remains the same as in the
previous section. Prior distributions are also expressed similarly. The covariance parameters follow a uniform prior distribution whose
limits are determined by se1i and se2i .
B.1 WinBUGS program for estimating bivariate hierarchical meta-analysis models of the sensitivity and specificity of a com-
parator test (T1) and a composite (T3) based on T1 and index test (T2) (T3+ = T1+ or T2+).
This program also provides the value of the index test (T2) as a new test over the alternative test (T1), while adjusting for the covariance
between T1 and T2 among disease positive. We did not model covariance among disease negatives as specificities were generally high.
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Observed data must be provided for L (the number of studies), the entries of the two-by-two table of index vs. the alternative test
separately in disease positive patients (T12˙D) and in disease negative patients (T12˙ND), the total number of disease positive (D) and
disease negative (ND) in each study. Initial values should be provided by the user for covsi , se1i and se2i .
--------------------------------------------------------------------------------------------------------------------------------
model {
for(i in 1:L) { # L is the number of studies
# Likelihood - within-studies
# 2 by 2 table between T1 and T2 in Disease+
T12˙D[i,1:4] ~ dmulti(pD[i,1:4], D[i])
# 2 by 2 table between T1 and T2 in Disease-
T12˙ND[i,1:4] ~ dmulti(pND[i,1:4], ND[i])
pD[i,1] <- se[1,i] * se[2,i] + covs[i] # P(t1=1, t2=1 | D=1)
pD[i,2] <- se[1,i] * (1-se[2,i]) - covs[i] # P(t1=1, t2=0 | D=1)
pD[i,3] <- (1-se[1,i]) * se[2,i] - covs[i] # P(t1=0, t2=1 | D=1)
pD[i,4] <- (1-se[1,i]) * (1-se[2,i]) + covs[i] # P(t1=0, t2=0 | D=1)
pND[i,1] <- sp[1,i] * sp[2,i] # P(t1=1, t2=1 | D=0)
pND [i,2] <- sp[1,i] * (1-sp[2,i]) # P(t1=1, t2=0 | D=0)
pND [i,3] <- (1-sp[1,i]) * sp[2,i] # P(t1=0, t2=1 | D=0)
pND [i,4] <- (1-sp[1,i]) * (1-sp[2,i]) # P(t1=0, t2=0 | D=0)
# lower limit of covariance in ith study
ll[i]<- -(1-se[1,i])*(1-se[2,i])
# upper limit of covariance in ith study
ul[i]<-min(se[1,i], se[2,i])- se[1,i]*se[2,i])
# prior over covariance in ith study
covs[i]~dunif(ll[i],ul[i])
# By definition of P(T3+|D+) = P(T1+, T2+|D+) + P(T1+, T2-|D+) + P(T1-, T2+|D+)
# and P(T3-|D-) = P(T1-, T2-|D-)
# Using this, we can express se2 and (1-sp2) in terms of the accuracies of the
# composite test and the alternative test and place priors on se2, sp2, se3 and
# sp3 as follows.
se[2,i] <- (se[3,i]-se[1,i] + covs[i]) / (1-se[1,i])
sp[2,i] <- sp[3,i] / sp[1,i]
# calculating logit sensitivities and specificities
logit(se[1, i]) <- l1[i,1]
logit(sp[1, i]) <- l1[i,2]
logit(se[3, i]) <- l3[i,1]
logit(sp[3, i]) <- l3[i,2]
# Likelihood - Between-studies
l1[i,1:2] ~ dmnorm(mu1[], T1[,])
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# Added value of T3 compared to T1
Add˙S<-Pooled˙S3-Pooled˙S1 # gain in sensitivity
Add˙C<-Pooled˙C3-Pooled˙C1 # gain in specificity
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or Xpert® MTB/RIF. In the review, we removed the word ’incremental’ because we thought it was confusing. Otherwise the methods
in the protocol, Shah 2014, and this review were similar.
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